BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49:777-782. [PMID: 11709511 DOI: 10.1136/gut.49.6.777] [Cited by in Crossref: 636] [Cited by in F6Publishing: 558] [Article Influence: 31.8] [Reference Citation Analysis]
Number Citing Articles
1 Simon EG, Samuel S, Ghosh S, Moran GW. Ustekinumab: a novel therapeutic option in Crohn's disease. Expert Opin Biol Ther 2016;16:1065-74. [PMID: 27341173 DOI: 10.1080/14712598.2016.1205582] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
2 Coffey JC, O‘leary DP, Kiernan MG, Faul P. The mesentery in Crohn's disease: friend or foe? Current Opinion in Gastroenterology 2016;32:267-73. [DOI: 10.1097/mog.0000000000000280] [Cited by in Crossref: 59] [Cited by in F6Publishing: 12] [Article Influence: 11.8] [Reference Citation Analysis]
3 Pigneur B, Seksik P, Viola S, Viala J, Beaugerie L, Girardet JP, Ruemmele FM, Cosnes J. Natural history of Crohn's disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010;16:953-961. [PMID: 19834970 DOI: 10.1002/ibd.21152] [Cited by in Crossref: 158] [Cited by in F6Publishing: 130] [Article Influence: 14.4] [Reference Citation Analysis]
4 Collins PD. Video capsule endoscopy in inflammatory bowel disease. World J Gastrointest Endosc 2016;8:477-88. [PMID: 27499830 DOI: 10.4253/wjge.v8.i14.477] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
5 Hall BJ, Holleran GE, Smith SM, Mahmud N, Mcnamara DA. A prospective 12-week mucosal healing assessment of small bowel Crohn’s disease as detected by capsule endoscopy. European Journal of Gastroenterology & Hepatology 2014;26:1253-9. [DOI: 10.1097/meg.0000000000000194] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 3.6] [Reference Citation Analysis]
6 Aldhous MC, Drummond HE, Anderson N, Smith LA, Arnott ID, Satsangi J. Does cigarette smoking influence the phenotype of Crohn's disease? Analysis using the Montreal classification. Am J Gastroenterol 2007;102:577-88. [PMID: 17338736 DOI: 10.1111/j.1572-0241.2007.01064.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 77] [Article Influence: 4.9] [Reference Citation Analysis]
7 Taylor SA, Mallett S, Bhatnagar G, Baldwin-Cleland R, Bloom S, Gupta A, Hamlin PJ, Hart AL, Higginson A, Jacobs I, McCartney S, Miles A, Murray CD, Plumb AA, Pollok RC, Punwani S, Quinn L, Rodriguez-Justo M, Shabir Z, Slater A, Tolan D, Travis S, Windsor A, Wylie P, Zealley I, Halligan S; METRIC study investigators. Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn's disease (METRIC): a multicentre trial. Lancet Gastroenterol Hepatol. 2018;3:548-558. [PMID: 29914843 DOI: 10.1016/s2468-1253(18)30161-4] [Cited by in Crossref: 59] [Cited by in F6Publishing: 17] [Article Influence: 19.7] [Reference Citation Analysis]
8 Russell RK, Satsangi J. IBD: a family affair. Best Pract Res Clin Gastroenterol. 2004;18:525-539. [PMID: 15157825 DOI: 10.1016/j.bpg.2003.12.006] [Cited by in Crossref: 87] [Cited by in F6Publishing: 73] [Article Influence: 5.1] [Reference Citation Analysis]
9 Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785-1794. [PMID: 21530745 DOI: 10.1053/j.gastro.2011.01.055] [Cited by in Crossref: 1157] [Cited by in F6Publishing: 978] [Article Influence: 115.7] [Reference Citation Analysis]
10 Kim NH, Jung YS, Moon CM, Lee SY, Kim ER, Kim YH, Lee CK, Lee SH, Kim JH, Huh KC, Yoon SM, Song HJ, Boo SJ, Jang HJ, Kim YS, Lee KM, Shin JE, Park DI. Long-term clinical outcomes of korean patient with Crohn's disease following early use of infliximab. Intest Res 2014;12:281-6. [PMID: 25374493 DOI: 10.5217/ir.2014.12.4.281] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
11 Casals-Pascual C, González A, Vázquez-Baeza Y, Song SJ, Jiang L, Knight R. Microbial Diversity in Clinical Microbiome Studies: Sample Size and Statistical Power Considerations.Gastroenterology. 2020;158:1524-1528. [PMID: 31930986 DOI: 10.1053/j.gastro.2019.11.305] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
12 Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104:465-83; quiz 464, 484. [PMID: 19174807 DOI: 10.1038/ajg.2008.168] [Cited by in Crossref: 606] [Cited by in F6Publishing: 491] [Article Influence: 50.5] [Reference Citation Analysis]
13 Boirivant M, Cossu A. Inflammatory bowel disease. Oral Dis. 2012;18:1-15. [PMID: 21564424 DOI: 10.1111/j.1601-0825.2011.01811.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
14 Srinath A, Young E, Szigethy E. Pain management in patients with inflammatory bowel disease: translational approaches from bench to bedside. Inflamm Bowel Dis 2014;20:2433-49. [PMID: 25208108 DOI: 10.1097/MIB.0000000000000170] [Cited by in Crossref: 45] [Cited by in F6Publishing: 21] [Article Influence: 7.5] [Reference Citation Analysis]
15 Cantó E, Ricart E, Busquets D, Monfort D, García-Planella E, González D, Balanzó J, Rodriguez-Sanchez JL, Vidal S. Influence of a nucleotide oligomerization domain 1 (NOD1) polymorphism and NOD2 mutant alleles on Crohn's disease phenotype. World J Gastroenterol 2007;13:5446-53. [PMID: 17907287 DOI: 10.3748/wjg.v13.i41.5446] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
16 Gordon IO, Agrawal N, Goldblum JR, Fiocchi C, Rieder F. Fibrosis in ulcerative colitis: mechanisms, features, and consequences of a neglected problem. Inflamm Bowel Dis. 2014;20:2198-2206. [PMID: 24892966 DOI: 10.1097/mib.0000000000000080] [Cited by in Crossref: 59] [Cited by in F6Publishing: 25] [Article Influence: 9.8] [Reference Citation Analysis]
17 Cerqueira RM, Lago PM. Clinical factors predictive of Crohn’s disease complications and surgery. Eur J Gastroenterol Hepatol. 2013;25:129-134. [PMID: 23104203 DOI: 10.1097/meg.0b013e32835a7eed] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
18 Odes S, Vardi H, Friger M, Wolters F, Hoie O, Moum B, Bernklev T, Yona H, Russel M, Munkholm P. Effect of phenotype on health care costs in Crohn’s disease: A European study using the Montreal classification. J Crohns Colitis. 2007;1:87-96. [PMID: 21172190 DOI: 10.1016/j.crohns.2007.08.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
19 Kim E, Yune S, Ha JM, Lee WJ, Hwang J, Min SY, Hong SN, Chang DK, Rhee P, Kim JJ, Kim Y. Predictive Factors of Response to Medical Therapy in Crohn's Disease Patients with Intestinal Obstruction. Korean J Gastroenterol 2013;62:213. [DOI: 10.4166/kjg.2013.62.4.213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Wang MH, Friton JJ, Raffals LE, Leighton JA, Pasha SF, Picco MF, Monroe K, Nix BD, Newberry RD, Faubion WA. Novel Genetic Variant Predicts Surgical Recurrence Risk in Crohn's Disease Patients. Inflamm Bowel Dis 2021:izaa362. [PMID: 33724339 DOI: 10.1093/ibd/izaa362] [Reference Citation Analysis]
21 Freeman HJ. Application of the Montreal classification for Crohn’s disease to a single clinician database of 1015 patients. Can J Gastroenterol. 2007;21:363-366. [PMID: 17571169 DOI: 10.1155/2007/951526] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
22 Park JJ, Yang SK, Ye BD, Kim JW, Park DI, Yoon H, Im JP, Lee KM, Yoon SN, Lee H; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of Crohn's disease. Intest Res 2017;15:38-67. [PMID: 28239314 DOI: 10.5217/ir.2017.15.1.38] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
23 Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol 2012;27:1266-80. [PMID: 22497584 DOI: 10.1111/j.1440-1746.2012.07150.x] [Cited by in Crossref: 195] [Cited by in F6Publishing: 185] [Article Influence: 21.7] [Reference Citation Analysis]
24 Gu YB, Zhong J;  Chinese IBD Endoscopic Club. Endoscopic management of stricturing Crohn's disease. J Dig Dis. 2020;21:351-354. [PMID: 32537911 DOI: 10.1111/1751-2980.12914] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Fiorino G, Bonifacio C, Allocca M, Danese S. Impact of therapies on bowel damage in Crohn's disease. United European Gastroenterol J 2020;8:410-7. [PMID: 32213030 DOI: 10.1177/2050640620908696] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
26 Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, Chowers Y, D'Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV Jr, Louis E, Michetti P, Munkholm P, Oresland T, Panés J, Peyrin-Biroulet L, Reinisch W, Sands BE, Schoelmerich J, Schreiber S, Tilg H, Travis S, van Assche G, Vecchi M, Mary JY, Colombel JF, Lémann M. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis 2011;17:1415-22. [PMID: 21560202 DOI: 10.1002/ibd.21506] [Cited by in Crossref: 360] [Cited by in F6Publishing: 291] [Article Influence: 32.7] [Reference Citation Analysis]
27 Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, Norman GL, Altstock RT, Van Steen K, Rutgeerts P, Van Assche G, Vermeire S. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007;56:1394-403. [PMID: 17456509 DOI: 10.1136/gut.2006.108043] [Cited by in Crossref: 217] [Cited by in F6Publishing: 189] [Article Influence: 15.5] [Reference Citation Analysis]
28 Veloso FT. Clinical predictors of Crohn’s disease course: . European Journal of Gastroenterology & Hepatology 2016;28:1122-5. [DOI: 10.1097/meg.0000000000000698] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
29 Allocca M, Danese S, Laurent V, Peyrin-Biroulet L. Use of Cross-Sectional Imaging for Tight Monitoring of Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020;18:1309-1323.e4. [PMID: 31812657 DOI: 10.1016/j.cgh.2019.11.052] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
30 El Ouali S, Click B, Holubar SD, Rieder F. Natural history, diagnosis and treatment approach to fibrostenosing Crohn's disease. United European Gastroenterol J 2020;8:263-70. [PMID: 32213020 DOI: 10.1177/2050640620901960] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
31 Eglinton T, Reilly M, Chang C, Barclay M, Frizelle F, Gearry R. Ileal disease is associated with surgery for perianal disease in a population-based Crohn's disease cohort. Br J Surg 2010;97:1103-9. [PMID: 20632279 DOI: 10.1002/bjs.7031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
32 Fumery M, Pariente B, Sarter H, Savoye G, Spyckerelle C, Djeddi D, Mouterde O, Bouguen G, Ley D, Peneau A, Dupas J, Turck D, Gower-rousseau C. Long-term outcome of pediatric-onset Crohn’s disease: A population-based cohort study. Digestive and Liver Disease 2019;51:496-502. [DOI: 10.1016/j.dld.2018.11.033] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 8.5] [Reference Citation Analysis]
33 Joyce MR, Hannaway CD, Strong SA, Fazio VW, Kiran RP. Impact of smoking on disease phenotype and postoperative outcomes for Crohn's disease patients undergoing surgery. Langenbecks Arch Surg 2013;398:39-45. [PMID: 22038296 DOI: 10.1007/s00423-011-0865-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
34 Colombel J. The CARD15 (also known as NOD2) gene in Crohn's disease: Are there implications for current clinical practice? Clinical Gastroenterology and Hepatology 2003;1:5-9. [DOI: 10.1053/jcgh.2003.50002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
35 Sahni AV, Shyn PB. Predicting the need for surgery in obstructive Crohnʼs disease: How hot is PET/CT? Inflammatory Bowel Diseases 2010;16:2182-3. [DOI: 10.1002/ibd.21335] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Louis E, Michel V, Hugot JP, Reenaers C, Fontaine F, Delforge M, El Yafi F, Colombel JF, Belaiche J. Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut. 2003;52:552-557. [PMID: 12631668 DOI: 10.1136/gut.52.4.552] [Cited by in Crossref: 181] [Cited by in F6Publishing: 171] [Article Influence: 10.1] [Reference Citation Analysis]
37 Treton X, Stefanescu C, Attar A, Alves A, Zappa M, Bouhnik Y. Sténose iléale. Gastroentérologie Clinique et Biologique 2007;31:387-92. [DOI: 10.1016/s0399-8320(07)89397-3] [Cited by in Crossref: 6] [Article Influence: 0.4] [Reference Citation Analysis]
38 Zankel E, Rogler G, Andus T, Reng CM, Schölmerich J, Timmer A. Crohn's disease patient characteristics in a tertiary referral center: comparison with patients from a population-based cohort. Eur J Gastroenterol Hepatol. 2005;17:395-401. [PMID: 15756091 DOI: 10.1097/00042737-200504000-00002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
39 Freeman HJ. Natural history and long-term clinical course of Crohn's disease. World J Gastroenterol. 2014;20:31-36. [PMID: 24415855 DOI: 10.3748/wjg.v20.i1.31] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 49] [Article Influence: 9.3] [Reference Citation Analysis]
40 Ahmad T, Tamboli CP, Jewell D, Colombel JF. Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology. 2004;126:1533-1549. [PMID: 15168365 DOI: 10.1053/j.gastro.2004.01.061] [Cited by in Crossref: 126] [Cited by in F6Publishing: 108] [Article Influence: 7.4] [Reference Citation Analysis]
41 Pariente B, Peyrin-Biroulet L, Cohen L, Zagdanski AM, Colombel JF. Gastroenterology review and perspective: the role of cross-sectional imaging in evaluating bowel damage in Crohn disease. AJR Am J Roentgenol. 2011;197:42-49. [PMID: 21701009 DOI: 10.2214/ajr.11.6632] [Cited by in Crossref: 39] [Cited by in F6Publishing: 12] [Article Influence: 3.9] [Reference Citation Analysis]
42 Rodríguez-lago I, Gisbert JP. The Role of Immunomodulators and Biologics in the Medical Management of Stricturing Crohn’s Disease. Journal of Crohn's and Colitis 2020;14:557-66. [DOI: 10.1093/ecco-jcc/jjz158] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
43 Leong RW, Lau JY, Sung JJ. The epidemiology and phenotype of Crohn's disease in the Chinese population. Inflamm Bowel Dis. 2004;10:646-651. [PMID: 15472528 DOI: 10.1097/00054725-200409000-00022] [Cited by in Crossref: 157] [Cited by in F6Publishing: 143] [Article Influence: 9.2] [Reference Citation Analysis]
44 Caprilli R, Angelucci E, Cocco A. Early or late guided missile in the treatment of Crohn's disease? Dig Liver Dis 2005;37:973-9. [PMID: 16169305 DOI: 10.1016/j.dld.2005.07.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
45 Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn's disease. Dis Mon. 2018;64:20-57. [PMID: 28826742 DOI: 10.1016/j.disamonth.2017.07.001] [Cited by in Crossref: 108] [Cited by in F6Publishing: 77] [Article Influence: 27.0] [Reference Citation Analysis]
46 Ahmad T, Armuzzi A, Bunce M, Mulcahy–hawes K, Marshall SE, Orchard TR, Crawshaw J, Large O, De Silva A, Cook JT, Barnardo M, Cullen S, Welsh KI, Jewell DP. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002;122:854-66. [DOI: 10.1053/gast.2002.32413] [Cited by in Crossref: 414] [Cited by in F6Publishing: 394] [Article Influence: 21.8] [Reference Citation Analysis]
47 Herfarth H, Göke M, Hellerbrand C, Mühlbauer M, Vogl D, Schölmerich J, Rogler G. Polymorphism of monocyte chemoattractant protein 1 in Crohn's disease. Int J Colorectal Dis. 2003;18:401-405. [PMID: 12904997 DOI: 10.1007/s00384-003-0477-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
48 Fowler SA, Ananthakrishnan AN, Gardet A, Stevens CR, Korzenik JR, Sands BE, Daly MJ, Xavier RJ, Yajnik V. SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease. J Crohns Colitis 2014;8:845-51. [PMID: 24461721 DOI: 10.1016/j.crohns.2014.01.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
49 Klein A, Mazor Y, Karban A, Ben-Itzhak O, Chowers Y, Sabo E. Early histological findings may predict the clinical phenotype in Crohn's colitis. United European Gastroenterol J. 2017;5:694-701. [PMID: 28815033 DOI: 10.1177/2050640616676435] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
50 Vermeire S, van Assche G, Rutgeerts P. Review article: Altering the natural history of Crohn’s disease--evidence for and against current therapies. Aliment Pharmacol Ther. 2007;25:3-12. [PMID: 17229216 DOI: 10.1111/j.1365-2036.2006.03134.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 35] [Article Influence: 0.7] [Reference Citation Analysis]
51 Chow DK, Leong RW, Lai LH, Wong GL, Leung WK, Chan FK, Sung JJ. Changes in Crohn’s disease phenotype over time in the Chinese population: validation of the Montreal classification system. Inflamm Bowel Dis. 2008;14:536-541. [PMID: 18058793 DOI: 10.1002/ibd.20335] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 4.2] [Reference Citation Analysis]
52 Crespi M, Dulbecco P, De Ceglie A, Conio M. Strictures in Crohn's Disease: From Pathophysiology to Treatment. Dig Dis Sci 2020;65:1904-16. [PMID: 32279173 DOI: 10.1007/s10620-020-06227-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
53 Unkart JT, Anderson L, Li E, Miller C, Yan Y, Gu CC, Chen J, Stone CD, Hunt S, Dietz DW. Risk factors for surgical recurrence after ileocolic resection of Crohn’s disease. Dis Colon Rectum. 2008;51:1211-1216. [PMID: 18536967 DOI: 10.1007/s10350-008-9348-7] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
54 Charpentier C, Salleron J, Savoye G, Fumery M, Merle V, Laberenne JE, Vasseur F, Dupas JL, Cortot A, Dauchet L, Peyrin-Biroulet L, Lerebours E, Colombel JF, Gower-Rousseau C. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63:423-432. [PMID: 23408350 DOI: 10.1136/gutjnl-2012-303864] [Cited by in Crossref: 188] [Cited by in F6Publishing: 160] [Article Influence: 23.5] [Reference Citation Analysis]
55 Moran GW, Dubeau MF, Kaplan GG, Yang H, Seow CH, Fedorak RN, Dieleman LA, Barkema HW, Ghosh S, Panaccione R. Phenotypic features of Crohn’s disease associated with failure of medical treatment. Clin Gastroenterol Hepatol. 2014;12:434-42.e1. [PMID: 23978351 DOI: 10.1016/j.cgh.2013.08.026] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
56 Aljebreen AM, Alharbi OR, Azzam NA, Almalki AS, Alswat KA, Almadi MA. Clinical epidemiology and phenotypic characteristics of Crohn's disease in the central region of Saudi Arabia. Saudi J Gastroenterol 2014;20:162-9. [PMID: 24976279 DOI: 10.4103/1319-3767.132993] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
57 Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, Ochsenkühn T, Orchard T, Rogler G, Louis E. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis. J Crohns Colitis. 2010;4:7-27. [PMID: 21122488 DOI: 10.1136/gut.2005.081950a] [Cited by in Crossref: 370] [Cited by in F6Publishing: 316] [Article Influence: 33.6] [Reference Citation Analysis]
58 Rieder F, Fiocchi C. Intestinal fibrosis in inflammatory bowel disease - Current knowledge and future perspectives. J Crohns Colitis. 2008;2:279-290. [PMID: 21172225 DOI: 10.1016/j.crohns.2008.05.009] [Cited by in Crossref: 86] [Cited by in F6Publishing: 81] [Article Influence: 6.6] [Reference Citation Analysis]
59 Pariente B, Mary JY, Danese S, Chowers Y, De Cruz P, D’Haens G, Loftus EV, Louis E, Panés J, Schölmerich J. Development of the Lémann index to assess digestive tract damage in patients with Crohn’s disease. Gastroenterology. 2015;148:52-63.e3. [PMID: 25241327 DOI: 10.1053/j.gastro.2014.09.015] [Cited by in Crossref: 183] [Cited by in F6Publishing: 151] [Article Influence: 26.1] [Reference Citation Analysis]
60 Morar PS, Faiz O, Warusavitarne J, Brown S, Cohen R, Hind D, Abercrombie J, Ragunath K, Sanders DS, Arnott I, Wilson G, Bloom S, Arebi N; Crohn's Stricture Study (CroSS) Group. Systematic review with meta-analysis: endoscopic balloon dilatation for Crohn's disease strictures. Aliment Pharmacol Ther. 2015;42:1137-1148. [PMID: 26358739 DOI: 10.1111/apt.13388] [Cited by in Crossref: 59] [Cited by in F6Publishing: 46] [Article Influence: 9.8] [Reference Citation Analysis]
61 Despott EJ, Fraser C. Small bowel endoscopy in inflammatory bowel disease. Best Practice & Research Clinical Gastroenterology 2012;26:279-91. [DOI: 10.1016/j.bpg.2012.01.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
62 Uchiyama K, Kishi H, Komatsu W, Nagao M, Ohhira S, Kobashi G. Lipid and Bile Acid Dysmetabolism in Crohn's Disease. J Immunol Res 2018;2018:7270486. [PMID: 30402511 DOI: 10.1155/2018/7270486] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
63 Lakatos L, Mester G, Erdelyi Z, Balogh M, Szipocs I, Kamaras G, Lakatos PL. Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977-2001. World J Gastroenterol 2004;10:404-9. [PMID: 14760767 DOI: 10.3748/wjg.v10.i3.404] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 76] [Article Influence: 4.1] [Reference Citation Analysis]
64 Pallotta N, Barberani F, Hassan NA, Guagnozzi D, Vincoli G, Corazziari E. Effect of infliximab on small bowel stenoses in patients with Crohn's disease. World J Gastroenterol 2008;14:1885-90. [PMID: 18350627 DOI: 10.3748/wjg.14.1885] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 39] [Article Influence: 3.7] [Reference Citation Analysis]
65 Shen B, Fazio VW, Remzi FH, Bennett AE, Brzezinski A, Lopez R, Oikonomou I, Sherman KK, Lashner B. Risk Factors for Clinical Phenotypes of Crohn's Disease of the Ileal Pouch. Am J Gastroenterology 2006;101:2760-8. [DOI: 10.1111/j.1572-0241.2006.00838.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 63] [Article Influence: 5.8] [Reference Citation Analysis]
66 Heidemann J, Domschke W, Kucharzik T, Maaser C. Intestinal microvascular endothelium and innate immunity in inflammatory bowel disease: a second line of defense? Infect Immun. 2006;74:5425-5432. [PMID: 16988217 DOI: 10.1128/iai.00248-06] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
67 Eglinton TW, Gearry RB. Clinical factors predicting disease course in Crohn’s disease. Expert Review of Clinical Immunology 2014;6:41-5. [DOI: 10.1586/eci.09.76] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
68 Hazelgrove KB, Flynn RS, Qiao LY, Grider JR, Kuemmerle JF. Endogenous IGF-I and alpha v beta3 integrin ligands regulate increased smooth muscle growth in TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol. 2009;296:G1230-G1237. [PMID: 19359426 DOI: 10.1152/ajpgi.90508.2008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
69 Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753. [PMID: 16698746 DOI: 10.1136/gut.2005.082909] [Cited by in Crossref: 1668] [Cited by in F6Publishing: 1466] [Article Influence: 111.2] [Reference Citation Analysis]
70 Scimeca D, Mocciaro F, Cottone M, Montalbano LM, D’Amico G, Olivo M, Orlando R, Orlando A. Efficacy and safety of endoscopic balloon dilation of symptomatic intestinal Crohn’s disease strictures. Dig Liver Dis. 2011;43:121-125. [PMID: 20561831 DOI: 10.1016/j.dld.2010.05.001] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 5.2] [Reference Citation Analysis]
71 Dewulf Nde L, Monteiro RA, Passos AD, Vieira EM, Troncon LE. [Compliance to drug therapy in inflammatory bowel diseases outpatients from a university hospital]. Arq Gastroenterol 2007;44:289-96. [PMID: 18317646 DOI: 10.1590/s0004-28032007000400003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
72 Patel SH, Rachchh MA, Jadav PD. Evaluation of anti-inflammatory effect of anti-platelet agent-clopidogrel in experimentally induced inflammatory bowel disease. Indian J Pharmacol. 2012;44:744-748. [PMID: 23248405 DOI: 10.4103/0253-7613.103278] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
73 Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, Landers CJ, Abreu-Martin MT, Rotter JI, Yang H, Targan SR. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004;126:414-424. [PMID: 14762777 DOI: 10.1053/j.gastro.2003.11.015] [Cited by in Crossref: 357] [Cited by in F6Publishing: 329] [Article Influence: 21.0] [Reference Citation Analysis]
74 Seow CH, Benchimol EI, Steinhart AH, Griffiths AM, Otley AR. Budesonide for Crohn's disease. Expert Opinion on Drug Metabolism & Toxicology 2009;5:971-9. [DOI: 10.1517/17425250903124355] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
75 Lakatos PL, Kiss LS. Current status of thiopurine analogues in the treatment in Crohn’s disease. World J Gastroenterol. 2011;17:4372-4381. [PMID: 22110262 DOI: 10.3748/wjg.v17.i39.4372] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
76 Lee KY, Yu CS, Lee KY, Cho YB, Park KJ, Choi GS, Yoon SN, Yoo H; IBD Study Group, Korean Society of Coloproctology. Risk factors for repeat abdominal surgery in korean patients with Crohn's disease: a multi-center study of a korean inflammatory bowel disease study group. J Korean Soc Coloproctol 2012;28:188-94. [PMID: 22993704 DOI: 10.3393/jksc.2012.28.4.188] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
77 Louis E, Van Kemseke C, Reenaers C. Necessity of phenotypic classification of inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2011;25 Suppl 1:S2-7. [PMID: 21640927 DOI: 10.1016/S1521-6918(11)70003-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
78 Sachar DB. Genomics and phenomics in Crohn's disease. Gastroenterology 2002;122:1161-2. [PMID: 11910366 DOI: 10.1053/gast.2002.32754] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
79 Bhattacharya A, Rao BB, Koutroubakis IE, Click B, Vargas EJ, Regueiro M, Schwartz M, Swoger JM, Babichenko D, Hartmann D, Rivers CR, Barrie A, Hashash JG, Dunn MA, Binion DG. Silent Crohn's Disease Predicts Increased Bowel Damage During Multiyear Follow-up: The Consequences of Under-reporting Active Inflammation. Inflamm Bowel Dis. 2016;22:2665-2671. [PMID: 27753691 DOI: 10.1097/mib.0000000000000935] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
80 Henriksen M, Jahnsen J, Lygren I, Aadland E, Schulz T, Vatn MH, Moum B, The Ibsen Study Group. Clinical course in Crohn's disease: Results of a five-year population-based follow-up study (the IBSEN study). Scandinavian Journal of Gastroenterology 2009;42:602-10. [DOI: 10.1080/00365520601076124] [Cited by in Crossref: 138] [Cited by in F6Publishing: 104] [Article Influence: 11.5] [Reference Citation Analysis]
81 Fagagnini S, Heinrich H, Rossel JB, Biedermann L, Frei P, Zeitz J, Spalinger M, Battegay E, Zimmerli L, Vavricka SR, Rogler G, Scharl M, Misselwitz B. Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. PLoS One 2017;12:e0185193. [PMID: 29023532 DOI: 10.1371/journal.pone.0185193] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
82 Shyn PB, Mortele KJ, Britz-Cunningham SH, Friedman S, Odze RD, Burakoff R, Goldberg JE, Erturk M, Silverman SG. Low-dose 18F-FDG PET/CT enterography: improving on CT enterography assessment of patients with Crohn disease. J Nucl Med 2010;51:1841-8. [PMID: 21078803 DOI: 10.2967/jnumed.110.080796] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
83 Goldstein NS. Isolated Ileal Erosions in Patients With Mildly Altered Bowel Habits: A Follow-up Study of 28 Patients. Am J Clin Pathol 2006;125:838-46. [DOI: 10.1309/4pk0g68m2g1l6x47] [Cited by in Crossref: 21] [Article Influence: 1.4] [Reference Citation Analysis]
84 Rimola J, Capozzi N. Differentiation of fibrotic and inflammatory component of Crohn's disease-associated strictures. Intest Res 2020;18:144-50. [PMID: 32326668 DOI: 10.5217/ir.2020.00015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
85 Cukovic-cavka S, Vermeire S, Hrstic I, Claessens G, Kolacek S, Jakic-razumovic J, Krznaric Z, Grubelic K, Radic D, Misak Z, Jadresin O, Rutgeerts P, Vucelic B. NOD2/CARD15 mutations in Croatian patients with Crohn??s disease: prevalence and genotype???phenotype relationship: . European Journal of Gastroenterology & Hepatology 2006;18:895-9. [DOI: 10.1097/00042737-200608000-00016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
86 Kedia S, Sharma R, Makharia GK, Ahuja V, Desai D, Kandasamy D, Eapen A, Ganesan K, Ghoshal UC, Kalra N, Karthikeyan D, Madhusudhan KS, Philip M, Puri AS, Puri S, Sinha SK, Banerjee R, Bhatia S, Bhat N, Dadhich S, Dhali GK, Goswami BD, Issar SK, Jayanthi V, Misra SP, Nijhawan S, Puri P, Sarkar A, Singh SP, Srivastava A, Abraham P, Ramakrishna BS; for Indian Society of Gastroenterology Task Force on Inflammatory Bowel Disease. Imaging of the small intestine in Crohn's disease: Joint position statement of the Indian Society of Gastroenterology and Indian Radiological and Imaging Association. Indian J Gastroenterol. 2017;36:487-508. [PMID: 29307029 DOI: 10.1007/s12664-017-0804-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
87 Bharadwaj S, Tandon P, Kulkarni G, Rivas J, Charles R. The role of endoscopy in inflammatory bowel disease. J Dig Dis. 2015;16:689-698. [PMID: 26595156 DOI: 10.1111/1751-2980.12301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
88 Jacene HA, Ginsburg P, Kwon J, Nguyen GC, Montgomery EA, Bayless TM, Wahl RL. Prediction of the need for surgical intervention in obstructive Crohn’s disease by 18F-FDG PET/CT. J Nucl Med. 2009;50:1751-1759. [PMID: 19837758 DOI: 10.2967/jnumed.109.065466] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
89 Koslowski MJ, Kübler I, Chamaillard M, Schaeffeler E, Reinisch W, Wang G, Beisner J, Teml A, Peyrin-Biroulet L, Winter S, Herrlinger KR, Rutgeerts P, Vermeire S, Cooney R, Fellermann K, Jewell D, Bevins CL, Schwab M, Stange EF, Wehkamp J. Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease. PLoS One 2009;4:e4496. [PMID: 19221600 DOI: 10.1371/journal.pone.0004496] [Cited by in Crossref: 88] [Cited by in F6Publishing: 78] [Article Influence: 7.3] [Reference Citation Analysis]
90 Endo K, Takahashi S, Shiga H, Kakuta Y, Kinouchi Y, Shimosegawa T. Short and long-term outcomes of endoscopic balloon dilatation for Crohn's disease strictures. World J Gastroenterol 2013;19:86-91. [PMID: 23326167 DOI: 10.3748/wjg.v19.i1.86] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 35] [Article Influence: 5.5] [Reference Citation Analysis]
91 Picco MF. New studies on the role of smoking in inflammatory bowel disease: are we not beating a dead horse? Am J Gastroenterol 2007;102:598-600. [PMID: 17335449 DOI: 10.1111/j.1572-0241.2007.01059.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
92 Dillman JR, Stidham RW, Higgins PD, Moons DS, Johnson LA, Rubin JM. US elastography-derived shear wave velocity helps distinguish acutely inflamed from fibrotic bowel in a Crohn disease animal model. Radiology. 2013;267:757-766. [PMID: 23401585 DOI: 10.1148/radiol.13121775] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 8.3] [Reference Citation Analysis]
93 de’Angelis N, Carra MC, Borrelli O, Bizzarri B, Vincenzi F, Fornaroli F, De Caro G, de’Angelis GL. Short- and long-term efficacy of endoscopic balloon dilation in Crohn’s disease strictures. World J Gastroenterol. 2013;19:2660-2667. [PMID: 23674873 DOI: 10.3748/wjg.v19.i17.2660] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
94 Sans M, Tàssies D, Pellisé M, Espinosa G, Quintó L, Piqué JM, Reverter JC, Panés J. The 4G/4G genotype of the 4G/5G polymorphism of the type-1 plasminogen activator inhibitor (PAI-1) gene is a determinant of penetrating behaviour in patients with Crohn's disease. Aliment Pharmacol Ther 2003;17:1039-47. [PMID: 12694086 DOI: 10.1046/j.1365-2036.2003.01536.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
95 Blonski W, Buchner AM, Lichtenstein GR. Clinical predictors of aggressive/disabling disease: ulcerative colitis and crohn disease. Gastroenterol Clin North Am. 2012;41:443-462. [PMID: 22500528 DOI: 10.1016/j.gtc.2012.01.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
96 Henriksen M, Jahnsen J, Lygren I, Vatn MH, Moum B; IBSEN Study Group. Are there any differences in phenotype or disease course between familial and sporadic cases of inflammatory bowel disease? Am J Gastroenterol. 2007;102:1955-1963. [PMID: 17573793 DOI: 10.1111/j.1572-0241.2007.01368.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
97 Lakatos PL. Prediction of disease course in inflammatory bowel diseases. World J Gastroenterol. 2010;16:2589-2590. [PMID: 20518078 DOI: 10.3748/wjg.v16.i21.2589] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
98 Sleiman J, El Ouali S, Qazi T, Cohen B, Steele SR, Baker ME, Rieder F. Prevention and Treatment of Stricturing Crohn's Disease - Perspectives and Challenges. Expert Rev Gastroenterol Hepatol 2021;15:401-11. [PMID: 33225766 DOI: 10.1080/17474124.2021.1854732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Kubesch A, Rueter L, Farrag K, Krause T, Stienecker K, Hausmann J, Filmann N, Dignass A, Stein J, Blumenstein I. Short and Long-Term Effectiveness of Ustekinumab in Patients with Crohn's Disease: Real-World Data from a German IBD Cohort. J Clin Med 2019;8:E2140. [PMID: 31817134 DOI: 10.3390/jcm8122140] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
100 Siva S, Rubin DT, Gulotta G, Wroblewski K, Pekow J. Zinc Deficiency is Associated with Poor Clinical Outcomes in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:152-7. [PMID: 27930412 DOI: 10.1097/MIB.0000000000000989] [Cited by in Crossref: 49] [Cited by in F6Publishing: 28] [Article Influence: 16.3] [Reference Citation Analysis]
101 Migaleddu V, Quaia E, Scanu D, Carla S, Bertolotto M, Campisi G, Sirigu D, Virgilio G. Inflammatory activity in Crohn's disease: CE-US. Abdom Imaging 2011;36:142-8. [PMID: 20464392 DOI: 10.1007/s00261-010-9622-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
102 Chhaya V, Saxena S, Cecil E, Chatu S, Subramanian V, Curcin V, Majeed A, Pollok RC. The impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: a national population-based study of incident cases between 1989-2009. Aliment Pharmacol Ther. 2015;41:87-98. [PMID: 25382737 DOI: 10.1111/apt.13017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
103 Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194-1201. [PMID: 21723220 DOI: 10.1053/j.gastro.2011.06.054] [Cited by in Crossref: 582] [Cited by in F6Publishing: 488] [Article Influence: 58.2] [Reference Citation Analysis]
104 Shen B, Fazio VW, Remzi FH, Bennett AE, Lavery IC, Lopez R, Brezinski A, Sherman KK, Bambrick ML, Lashner BA. Clinical Features and Quality of Life in Patients with Different Phenotypes of Crohn's Disease of the Ileal Pouch. Diseases of the Colon & Rectum 2007;50:1450-9. [DOI: 10.1007/s10350-007-0284-8] [Cited by in Crossref: 64] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
105 Rueda Guzmán A, Wehkamp J, Kirschniak A, Naumann A, Malek NP, Goetz M. Endoscopic balloon dilatation of Crohn's-associated intestinal strictures: High patient satisfaction and long-term efficacy. United European Gastroenterol J 2016;4:794-9. [PMID: 28408997 DOI: 10.1177/2050640616628515] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
106 Smith BRK, Arnott IDR, Drummond HE, Nimmo ER, Satsangi J. Disease Location, Anti-Saccharomyces cerevisiae Antibody, and NOD2/CARD15 Genotype Influence the Progression of Disease Behavior in Crohn’s Disease: . Inflammatory Bowel Diseases 2004;10:521-8. [DOI: 10.1097/00054725-200409000-00005] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 4.2] [Reference Citation Analysis]
107 Jensen MD, Nathan T, Rafaelsen SR, Kjeldsen J. Diagnostic Accuracy of Capsule Endoscopy for Small Bowel Crohn's Disease Is Superior to That of MR Enterography or CT Enterography. Clinical Gastroenterology and Hepatology 2011;9:124-129.e1. [DOI: 10.1016/j.cgh.2010.10.019] [Cited by in Crossref: 157] [Cited by in F6Publishing: 132] [Article Influence: 15.7] [Reference Citation Analysis]
108 Ruemmele FM. Pediatric inflammatory bowel diseases: coming of age. Curr Opin Gastroenterol. 2010;26:332-336. [PMID: 20571385 DOI: 10.1097/mog.0b013e328339ec2d] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
109 Parisinos CA, McIntyre VE, Heron T, Subedi D, Arnott ID, Mowat C, Wilson DC, McGurk S, Glancy S, Zealley IA, Satsangi J, Lees CW. Magnetic resonance follow-through imaging for evaluation of disease activity in ileal Crohn's disease: an observational, retrospective cohort study. Inflamm Bowel Dis. 2010;16:1219-1226. [PMID: 19924804 DOI: 10.1002/ibd.21168] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
110 Suzuki H, Watanabe K, Kohyama A, Ohnuma S, Karasawa H, Kajiwara T, Kobayashi M, Hatsuzawa Y, Kamei T, Unno M. Resection rate curves by location along the small intestine provide perspectives on characteristics of Crohn's disease. Colorectal Dis 2021;23:1167-74. [PMID: 33325611 DOI: 10.1111/codi.15487] [Reference Citation Analysis]
111 Rieder F, Lawrance IC, Leite A, Sans M. Predictors of fibrostenotic Crohn's disease. Inflamm Bowel Dis. 2011;17:2000-2007. [PMID: 21308880 DOI: 10.1002/ibd.21627] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
112 Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F, Allez M, Dupas JL, Reimund JM, Savoye G. Early administration of azathioprine vs conventional management of Crohn’s Disease: a randomized controlled trial. Gastroenterology. 2013;145:758-765.e2; quiz e14-5. [PMID: 23644079 DOI: 10.1053/j.gastro.2013.04.048] [Cited by in Crossref: 191] [Cited by in F6Publishing: 147] [Article Influence: 23.9] [Reference Citation Analysis]
113 Burke JP, Mulsow JJ, O'Keane C, Docherty NG, Watson RW, O'Connell PR. Fibrogenesis in Crohn's disease. Am J Gastroenterol. 2007;102:439-448. [PMID: 17156147 DOI: 10.1111/j.1572-0241.2006.01010.x] [Cited by in Crossref: 189] [Cited by in F6Publishing: 182] [Article Influence: 12.6] [Reference Citation Analysis]
114 Arieira C, Cúrdia Gonçaves T, Dias de Castro F, João Moreira M, Cotter J. Clinical course in Crohn’s disease: factors associated with behaviour change and surgery. Scandinavian Journal of Gastroenterology 2018;53:1222-7. [DOI: 10.1080/00365521.2018.1503709] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
115 Schnitzler F, Brand S, Staudinger T, Pfennig S, Hofbauer K, Seiderer J, Tillack C, Göke B, Ochsenkühn T, Lohse P. Eight novel CARD15 variants detected by DNA sequence analysis of the CARD15 gene in 111 patients with inflammatory bowel disease. Immunogenetics 2006;58:99-106. [PMID: 16485124 DOI: 10.1007/s00251-005-0073-2] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 2.6] [Reference Citation Analysis]
116 Johnson LA, Luke A, Sauder K, Moons DS, Horowitz JC, Higgins PD. Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: impact of a “Top-Down” approach to intestinal fibrosis in mice. Inflamm Bowel Dis. 2012;18:460-471. [PMID: 21761511 DOI: 10.1002/ibd.21812] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 6.7] [Reference Citation Analysis]
117 Bessissow T, Reinglas J, Aruljothy A, Lakatos PL, Van Assche G. Endoscopic management of Crohn's strictures. World J Gastroenterol. 2018;24:1859-1867. [PMID: 29740201 DOI: 10.3748/wjg.v24.i17.1859] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
118 Velayos FS, Sandborn WJ. Positioning biologic therapy for Crohn’s disease and ulcerative colitis. Curr Gastroenterol Rep 2007;9:521-7. [DOI: 10.1007/s11894-007-0069-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
119 Kopylov U, Yablecovitch D, Lahat A, Neuman S, Levhar N, Greener T, Klang E, Rozendorn N, Amitai MM, Ben-Horin S, Eliakim R. Detection of Small Bowel Mucosal Healing and Deep Remission in Patients With Known Small Bowel Crohn's Disease Using Biomarkers, Capsule Endoscopy, and Imaging. Am J Gastroenterol. 2015;110:1316-1323. [PMID: 26215531 DOI: 10.1038/ajg.2015.221] [Cited by in Crossref: 86] [Cited by in F6Publishing: 81] [Article Influence: 14.3] [Reference Citation Analysis]
120 Adler J, Rangwalla SC, Dwamena BA, Higgins PD. The prognostic power of the NOD2 genotype for complicated Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2011;106:699-712. [PMID: 21343918 DOI: 10.1038/ajg.2011.19] [Cited by in Crossref: 119] [Cited by in F6Publishing: 99] [Article Influence: 11.9] [Reference Citation Analysis]
121 Ashton JJ, Coelho T, Ennis S, Batra A, Afzal NA, Beattie RM. Presenting phenotype of paediatric inflammatory bowel disease in Wessex, Southern England 2010-2013. Acta Paediatr. 2015;104:831-837. [PMID: 25847524 DOI: 10.1111/apa.13017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
122 Cosnes J, Bourrier A, Nion-Larmurier I, Sokol H, Beaugerie L, Seksik P. Factors affecting outcomes in Crohn's disease over 15 years. Gut. 2012;61:1140-1145. [PMID: 22387526 DOI: 10.1136/gutjnl-2011-301971] [Cited by in Crossref: 71] [Cited by in F6Publishing: 54] [Article Influence: 7.9] [Reference Citation Analysis]
123 Sapci I, Gorgun E. Minimally Invasive Surgery in Complex Crohn's Disease. Clin Colon Rectal Surg 2019;32:300-4. [PMID: 31275077 DOI: 10.1055/s-0039-1683922] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
124 Reenaers C, Pirard C, Vankemseke C, Latour P, Belaiche J, Louis E. Long-term evolution and predictive factors of mild inflammatory bowel disease. Scand J Gastroenterol 2016;51:712-9. [PMID: 26815198 DOI: 10.3109/00365521.2015.1128965] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
125 Chatzicostas C, Roussomoustakaki M, Potamianos S, Paspatis G, Mouzas I, Romanos J, Mavrogeni H, Kouroumalis E. Factors associated with disease evolution in Greek patients with inflammatory bowel disease. BMC Gastroenterol 2006;6:21. [PMID: 16869971 DOI: 10.1186/1471-230X-6-21] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
126 Heresbach D, Gicquel-Douabin V, Birebent B, D’halluin PN, Heresbach-Le Berre N, Dreano S, Siproudhis L, Dabadie A, Gosselin M, Mosser J. NOD2/CARD15 gene polymorphisms in Crohn’s disease: a genotype- phenotype analysis. Eur J Gastroenterol Hepatol. 2004;16:55-62. [PMID: 15095853 DOI: 10.1097/00042737-200401000-00009] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 3.1] [Reference Citation Analysis]
127 Kupka T, Simova J, Dvorackova J, Martinek L, Motyka O, Uvirova M, Dite P. Crohn's disease - genetic factors and progress of the disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2018;162:139-43. [PMID: 29358789 DOI: 10.5507/bp.2017.058] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
128 Al-Mofarreh MA, Al-Mofleh IA. Emerging inflammatory bowel disease in saudi outpatients: a report of 693 cases. Saudi J Gastroenterol. 2013;19:16-22. [PMID: 23319033 DOI: 10.4103/1319-3767.105915] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
129 Flynn S, Eisenstein S. Inflammatory Bowel Disease Presentation and Diagnosis. Surg Clin North Am 2019;99:1051-62. [PMID: 31676047 DOI: 10.1016/j.suc.2019.08.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
130 de Barros KSC, Flores C, Harlacher L, Francesconi CFM. Evolution of Clinical Behavior in Crohn's Disease: Factors Associated with Complicated Disease and Surgery. Dig Dis Sci 2017;62:2481-8. [PMID: 28748409 DOI: 10.1007/s10620-017-4685-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
131 Rentsch M, Beham A, Schlitt H, Jauch K. Crohn’s Disease Activity Index and Vienna Classification – Is It Worthwhile to Calculate before Surgery? Dig Surg 2006;23:241-9. [DOI: 10.1159/000095397] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
132 Cummings JR, Jewell DP. Clinical implications of inflammatory bowel disease genetics on phenotype. Inflamm Bowel Dis. 2005;11:56-61. [PMID: 15674114 DOI: 10.1097/00054725-200501000-00008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
133 Rozendorn N, Klang E, Lahat A, Yablecovitch D, Kopylov U, Eliakim A, Ben-Horin S, Amitai MM. Prediction of patency capsule retention in known Crohn’s disease patients by using magnetic resonance imaging. Gastrointest Endosc. 2016;83:182-187. [PMID: 26142554 DOI: 10.1016/j.gie.2015.05.048] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
134 Yao J, Jiang Y, Ke J, Lu Y, Hu J, Zhi M. A Validated Prognostic Model and Nomogram to Predict Early-Onset Complications Leading to Surgery in Patients With Crohn's Disease. Dis Colon Rectum 2021;64:697-705. [PMID: 33315712 DOI: 10.1097/DCR.0000000000001881] [Reference Citation Analysis]
135 Liefferinckx C, Franchimont D. Viewpoint: Toward the Genetic Architecture of Disease Severity in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2018;24:1428-39. [PMID: 29788122 DOI: 10.1093/ibd/izy109] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
136 Chen H, Lee A, Bowcock A, Zhu W, Li E, Ciorba M, Hunt S. Influence of Crohn's disease risk alleles and smoking on disease location. Dis Colon Rectum 2011;54:1020-5. [PMID: 21730793 DOI: 10.1007/DCR.0b013e31821b94b3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
137 Fadda MA, Peedikayil MC, Kagevi I, Kahtani KA, Ben AA, Al HI, Sohaibani FA, Quaiz MA, Abdulla M, Khan MQ, Helmy A. Inflammatory bowel disease in Saudi Arabia: a hospital-based clinical study of 312 patients. Ann Saudi Med. 2012;32:276-282. [PMID: 22588439 DOI: 10.5144/0256-4947.2012.276] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
138 Khoury T, Daher S, Massarwa M, Hakimian D, Benson AA, Viener E, Farah R, Mari A, Hazou W, Kadah A, Sbeit W, Mahamid M, Israeli E. A Validated Score Assessing the Risk of an Intra-Abdominal Abscess in Patients with Crohn's Disease Presenting at the Emergency Department. J Crohns Colitis 2019;13:1131-7. [PMID: 30768181 DOI: 10.1093/ecco-jcc/jjz043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
139 Laghi L, Costa S, Saibeni S, Bianchi P, Omodei P, Carrara A, Spina L, Contessini Avesani E, Vecchi M, De Franchis R, Malesci A. Carriage of CARD15 variants and smoking as risk factors for resective surgery in patients with Crohn's ileal disease. Aliment Pharmacol Ther 2005;22:557-64. [DOI: 10.1111/j.1365-2036.2005.02629.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
140 Amre DK, Lu SE, Costea F, Seidman EG. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn’s disease patients. Am J Gastroenterol. 2006;101:645-652. [PMID: 16464223 DOI: 10.1111/j.1572-0241.2006.00468.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 68] [Article Influence: 5.3] [Reference Citation Analysis]
141 Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389:1741-1755. [PMID: 27914655 DOI: 10.1016/s0140-6736(16)31711-1] [Cited by in Crossref: 615] [Cited by in F6Publishing: 245] [Article Influence: 123.0] [Reference Citation Analysis]
142 Schwartz DA, Wang A, Ozbay B, Skup M, Eichner SF, Lin J, Chao J. Comparison of Health Care Utilization and Costs Between Patients with Perianal Fistulizing Crohn's Disease Treated with Biologics with or Without Previous Seton Placement. Inflamm Bowel Dis 2017;23:1860-6. [PMID: 28858069 DOI: 10.1097/MIB.0000000000001243] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.7] [Reference Citation Analysis]
143 Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ. Crohn's disease complicated by strictures: a systematic review. Gut. 2013;62:1072-1084. [PMID: 23626373 DOI: 10.1136/gutjnl-2012-304353] [Cited by in Crossref: 243] [Cited by in F6Publishing: 200] [Article Influence: 30.4] [Reference Citation Analysis]
144 Al-hawary MM, Kaza RK, Platt JF. CT Enterography: Concepts and Advances in Crohn's Disease Imaging. Radiologic Clinics of North America 2013;51:1-16. [DOI: 10.1016/j.rcl.2012.09.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
145 Panes J, Bouhnik Y, Reinisch W, Stoker J, Taylor SA, Baumgart DC, Danese S, Halligan S, Marincek B, Matos C. Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis. 2013;7:556-585. [PMID: 23583097 DOI: 10.1016/j.crohns.2013.02.020] [Cited by in Crossref: 400] [Cited by in F6Publishing: 296] [Article Influence: 50.0] [Reference Citation Analysis]
146 Chiorean MV, Sandrasegaran K, Saxena R, Maglinte DD, Nakeeb A, Johnson CS. Correlation of CT enteroclysis with surgical pathology in Crohn’s disease. Am J Gastroenterol. 2007;102:2541-2550. [PMID: 17900329 DOI: 10.1111/j.1572-0241.2007.01537.x] [Cited by in Crossref: 157] [Cited by in F6Publishing: 132] [Article Influence: 11.2] [Reference Citation Analysis]
147 Lin MV, Blonski W, Lichtenstein GR. What is the optimal therapy for Crohn‘s disease: step-up or top-down? Expert Rev Gastroenterol Hepatol. 2010;4:167-180. [PMID: 20350264 DOI: 10.1586/egh.10.4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
148 Bernstein CN. The Natural History of Inflammatory Bowel Disease. In: Baumgart DC, editor. Crohn's Disease and Ulcerative Colitis. Boston: Springer US; 2012. pp. 343-63. [DOI: 10.1007/978-1-4614-0998-4_26] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
149 Achkar JP, Dassopoulos T, Silverberg MS, Tuvlin JA, Duerr RH, Brant SR, Siminovitch K, Reddy D, Datta LW, Bayless TM, Zhang L, Barmada MM, Rioux JD, Steinhart AH, McLeod RS, Griffiths AM, Cohen Z, Yang H, Bromfield GP, Schumm P, Hanauer SB, Cho JH, Nicolae DL. Phenotype-stratified genetic linkage study demonstrates that IBD2 is an extensive ulcerative colitis locus. Am J Gastroenterol 2006;101:572-80. [PMID: 16542294 DOI: 10.1111/j.1572-0241.2006.00451.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
150 Tavares de Sousa H, Estevinho MM, Peyrin-biroulet L, Danese S, Dias CC, Carneiro F, Magro F. Transmural Histological Scoring Systems in Crohn’s Disease: A Systematic Review With Assessment of Methodological Quality and Operating Properties. Journal of Crohn's and Colitis 2020;14:743-56. [DOI: 10.1093/ecco-jcc/jjz178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
151 Johnson LA, Rodansky ES, Sauder KL, Horowitz JC, Mih JD, Tschumperlin DJ, Higgins PD. Matrix stiffness corresponding to strictured bowel induces a fibrogenic response in human colonic fibroblasts.Inflamm Bowel Dis. 2013;19:891-903. [PMID: 23502354 DOI: 10.1097/MIB.0b013e3182813297] [Cited by in Crossref: 88] [Cited by in F6Publishing: 47] [Article Influence: 11.0] [Reference Citation Analysis]
152 Rivière P, D'Haens G, Peyrin-Biroulet L, Baert F, Lambrecht G, Pariente B, Bossuyt P, Buisson A, Oldenburg B, Vermeire S, Laharie D. Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX. Am J Gastroenterol 2021;116:134-41. [PMID: 33177349 DOI: 10.14309/ajg.0000000000000834] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
153 Lee DW, Koo JS, Choe JW, Suh SJ, Kim SY, Hyun JJ, Jung SW, Jung YK, Yim HJ, Lee SW. Diagnostic delay in inflammatory bowel disease increases the risk of intestinal surgery. World J Gastroenterol. 2017;23:6474-6481. [PMID: 29085197 DOI: 10.3748/wjg.v23.i35.6474] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
154 Odes S. How expensive is inflammatory bowel disease? A critical analysis. World J Gastroenterol. 2008;14:6641-6647. [PMID: 19034966 DOI: 10.3748/wjg.14.6641] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 48] [Article Influence: 3.8] [Reference Citation Analysis]
155 Obando C, Ding Z, Muser E, Vaidya N, Qiang W, Sun X, Wang H, Mallampati R, Xie L. Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn's Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States. Adv Ther 2020;37:2127-43. [PMID: 32193810 DOI: 10.1007/s12325-020-01276-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
156 de Melo SW, Di Palma JA. The Role of Capsule Endoscopy in Evaluating Inflammatory Bowel Disease. Gastroenterology Clinics of North America 2012;41:315-23. [DOI: 10.1016/j.gtc.2012.01.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
157 Hotta Y, Uchiyama K, Takagi T, Kashiwagi S, Nakano T, Mukai R, Toyokawa Y, Yasuda T, Ueda T, Suyama Y, Murakami T, Tanaka M, Majima A, Doi T, Hirai Y, Mizushima K, Morita M, Higashimura Y, Inoue K, Fukui A, Okayama T, Katada K, Kamada K, Handa O, Ishikawa T, Naito Y, Itoh Y. Transforming growth factor β1-induced collagen production in myofibroblasts is mediated by reactive oxygen species derived from NADPH oxidase 4. Biochem Biophys Res Commun 2018;506:557-62. [PMID: 30361098 DOI: 10.1016/j.bbrc.2018.10.116] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
158 Freeman HJ. Age-dependent phenotypic clinical expression of Crohn’s disease. J Clin Gastroenterol. 2005;39:774-777. [PMID: 16145338 DOI: 10.1097/01.mcg.0000177243.51967.ca] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
159 Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol. 2008;43:948-954. [PMID: 19086165 DOI: 10.1080/00365520801957149] [Cited by in Crossref: 194] [Cited by in F6Publishing: 172] [Article Influence: 16.2] [Reference Citation Analysis]
160 Freeman HJ. Long-term natural history of Crohn's disease. World J Gastroenterol. 2009;15:1315-1318. [PMID: 19294760 DOI: 10.3748/wjg.15.1315] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
161 Leyendecker JR, Bloomfeld RS, DiSantis DJ, Waters GS, Mott R, Bechtold RE. MR enterography in the management of patients with Crohn disease. Radiographics 2009;29:1827-46. [PMID: 19959524 DOI: 10.1148/rg.296095510] [Cited by in Crossref: 106] [Cited by in F6Publishing: 78] [Article Influence: 9.6] [Reference Citation Analysis]
162 Brant SR, Picco MF, Achkar JP, Bayless TM, Kane SV, Brzezinski A, Nouvet FJ, Bonen D, Karban A, Dassopoulos T. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn’s disease phenotypes. Inflamm Bowel Dis. 2003;9:281-289. [PMID: 14555911 DOI: 10.1097/00054725-200309000-00001] [Cited by in Crossref: 159] [Cited by in F6Publishing: 153] [Article Influence: 9.4] [Reference Citation Analysis]
163 Lahat A, Chowers Y. The patient with recurrent (sub) obstruction due to Crohn's disease. Best Practice & Research Clinical Gastroenterology 2007;21:427-44. [DOI: 10.1016/j.bpg.2007.02.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
164 Oldenburg B, Hommes D. Biological therapies in inflammatory bowel disease: top-down or bottom-up? Curr Opin Gastroenterol. 2007;23:395-399. [PMID: 17545775 DOI: 10.1097/mog.0b013e32815b601b] [Cited by in Crossref: 37] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
165 Kim ES, Kim WH. Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics. Gut Liver. 2010;4:1-14. [PMID: 20479907 DOI: 10.5009/gnl.2010.4.1.1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 5.7] [Reference Citation Analysis]
166 Mamula P, Markowitz JE, Baldassano RN. Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterol Clin North Am. 2003;32:967-95, viii. [PMID: 14562584 DOI: 10.1016/s0889-8553(03)00046-3] [Cited by in Crossref: 130] [Cited by in F6Publishing: 34] [Article Influence: 7.2] [Reference Citation Analysis]
167 Karczewski J, Swora-Cwynar E, Rzymski P, Poniedziałek B, Adamski Z. Selected biologic markers of inflammation and activity of Crohn's disease. Autoimmunity 2015;48:318-27. [PMID: 25707687 DOI: 10.3109/08916934.2015.1016221] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
168 Tulumović E, Salkić N, Tulumović D. Inflammatory bowel disease in Tuzla Canton, Bosnia-Herzegovina: A prospective 10-year follow-up. World J Gastroenterol 2021;27:2630-42. [PMID: 34092980 DOI: 10.3748/wjg.v27.i20.2630] [Reference Citation Analysis]
169 Oefferlbauer-Ernst A, Miehsler W, Eckmüllner O, Travis S, Waldhoer T, Dejaco C, Gangl A, Vogelsang H, Reinisch W. Impact of interobserver disagreement on phenotype-genotype associations in Crohn's disease. Inflamm Bowel Dis. 2007;13:156-163. [PMID: 17206717 DOI: 10.1002/ibd.20016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
170 Bettenworth D, Gustavsson A, Atreja A, Lopez R, Tysk C, van Assche G, Rieder F. A Pooled Analysis of Efficacy, Safety, and Long-term Outcome of Endoscopic Balloon Dilation Therapy for Patients with Stricturing Crohnʼs Disease: . Inflammatory Bowel Diseases 2017;23:133-42. [DOI: 10.1097/mib.0000000000000988] [Cited by in Crossref: 91] [Cited by in F6Publishing: 31] [Article Influence: 22.8] [Reference Citation Analysis]
171 Kim K, Johnson LA, Jia C, Joyce JC, Rangwalla S, Higgins PD, Rubin JM. Noninvasive ultrasound elasticity imaging (UEI) of Crohn’s disease: animal model. Ultrasound Med Biol. 2008;34:902-912. [PMID: 18294759 DOI: 10.1016/j.ultrasmedbio.2007.11.020] [Cited by in Crossref: 64] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
172 Li C, Kuemmerle JF. Mechanisms that mediate the development of fibrosis in patients with Crohn’s disease. Inflamm Bowel Dis. 2014;20:1250-1258. [PMID: 24831560 DOI: 10.1097/mib.0000000000000043] [Cited by in Crossref: 66] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
173 Hall B, Holleran G, Chin J, Smith S, Ryan B, Mahmud N, Mcnamara D. A prospective 52week mucosal healing assessment of small bowel Crohn's disease as detected by capsule endoscopy. Journal of Crohn's and Colitis 2014;8:1601-9. [DOI: 10.1016/j.crohns.2014.09.005] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 8.4] [Reference Citation Analysis]
174 Sans M, Masamunt MC. [Fibrogenesis and inflammatory bowel disease]. Gastroenterol Hepatol. 2007;30:36-41. [PMID: 17266880 DOI: 10.1157/13097449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
175 Sagami S, Kobayashi T, Kikkawa N, Umeda S, Nakano M, Toyonaga T, Okabayashi S, Ozaki R, Hibi T. Combination of colonoscopy and magnetic resonance enterography is more useful for clinical decision making than colonoscopy alone in patients with complicated Crohn's disease. PLoS One 2019;14:e0212404. [PMID: 30785943 DOI: 10.1371/journal.pone.0212404] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
176 Colombel JF, Louis E, Peyrin-Biroulet L, Sandborn WJ, Panaccione R. Deep remission: a new concept? Dig Dis. 2012;30 Suppl 3:107-111. [PMID: 23295700 DOI: 10.1159/000342732] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
177 Pierre N, Salée C, Vieujean S, Bequet E, Merli AM, Siegmund B, Meuwis MA, Louis E. Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology. Aliment Pharmacol Ther 2021;54:779-91. [PMID: 34297423 DOI: 10.1111/apt.16536] [Reference Citation Analysis]
178 O'Donnell S, Borowski K, Espin-Garcia O, Milgrom R, Kabakchiev B, Stempak J, Panikkath D, Eksteen B, Xu W, Steinhart AH, Kaplan GG, McGovern DPB, Silverberg MS. The Unsolved Link of Genetic Markers and Crohn's Disease Progression: A North American Cohort Experience. Inflamm Bowel Dis 2019;25:1541-9. [PMID: 30801121 DOI: 10.1093/ibd/izz016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
179 Sjöberg D, Holmström T, Larsson M, Nielsen AL, Holmquist L, Ekbom A, Rönnblom A. Incidence and clinical course of Crohn’s disease during the first year - results from the IBD Cohort of the Uppsala Region (ICURE) of Sweden 2005-2009. J Crohns Colitis. 2014;8:215-222. [PMID: 24035547 DOI: 10.1016/j.crohns.2013.08.009] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 9.1] [Reference Citation Analysis]
180 Palmieri O, Bossa F, Valvano MR, Corritore G, Latiano T, Martino G, D'Incà R, Cucchiara S, Pastore M, D'Altilia M, Scimeca D, Biscaglia G, Andriulli A, Latiano A. Crohn's Disease Localization Displays Different Predisposing Genetic Variants. PLoS One 2017;12:e0168821. [PMID: 28052082 DOI: 10.1371/journal.pone.0168821] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
181 Bodegraven AAV, Wijmenga C. Inflammatory Bowel Disease. Genomic and Personalized Medicine. Elsevier; 2009. pp. 1040-55. [DOI: 10.1016/b978-0-12-369420-1.00086-x] [Reference Citation Analysis]
182 Mak JWY, Lok Tung Ho C, Wong K, Cheng TY, Yip TCF, Leung WK, Li M, Lo FH, Ng KM, Sze SF, Leung CM, Tsang SWC, Shan EHS, Chan KH, Lam BCY, Hui AJ, Chow WH, Ng SC. Epidemiology and Natural History of Elderly-onset Inflammatory Bowel Disease: Results From a Territory-wide Hong Kong IBD Registry. J Crohns Colitis 2021;15:401-8. [PMID: 32914171 DOI: 10.1093/ecco-jcc/jjaa181] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
183 Koriche D, Gower-rousseau C, Chater C, Duhamel A, Salleron J, Tavernier N, Colombel J, Pariente B, Cortot A, Zerbib P. Post-operative recurrence of Crohn’s disease after definitive stoma: an underestimated risk. Int J Colorectal Dis 2017;32:453-8. [DOI: 10.1007/s00384-016-2707-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
184 Aaltonen G, Carpelan-holmström M, Keränen I, Lepistö A. Surgical recurrence in Crohn’s disease: a comparison between different types of bowel resections. Int J Colorectal Dis 2018;33:473-7. [DOI: 10.1007/s00384-018-2995-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
185 Rieder F, Fiocchi C. Intestinal fibrosis in IBD--a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol. 2009;6:228-235. [PMID: 19347014 DOI: 10.1038/nrgastro.2009.31] [Cited by in Crossref: 193] [Cited by in F6Publishing: 186] [Article Influence: 16.1] [Reference Citation Analysis]
186 Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015;50:942-951. [PMID: 25687629 DOI: 10.3109/00365521.2015.1014407] [Cited by in Crossref: 186] [Cited by in F6Publishing: 143] [Article Influence: 31.0] [Reference Citation Analysis]
187 Corrêa FF, Sdepanian VL. BODY IRON STATUS INDICATORS AND INFLAMMATION INDICATORS DURING INFLAMMATORY BOWEL DISEASE THERAPY IN CHILDREN AND ADOLESCENTES. Arq Gastroenterol 2021;58:48-54. [PMID: 33909796 DOI: 10.1590/S0004-2803.202100000-09] [Reference Citation Analysis]
188 Amezaga AJ, Van Assche G. Practical Approaches to "Top-Down" Therapies for Crohn's Disease. Curr Gastroenterol Rep 2016;18:35. [PMID: 27184044 DOI: 10.1007/s11894-016-0507-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
189 Louis E, Reenaers C, Belaiche J. Does the phenotype at diagnosis (e.g., fibrostenosing, inflammatory, perforating) predict the course of Crohnʼs disease?: . Inflammatory Bowel Diseases 2008;14:S59-60. [DOI: 10.1002/ibd.20559] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
190 Jürgens M, Brand S, Laubender RP, Seiderer J, Glas J, Wetzke M, Wagner J, Pfennig S, Tillack C, Beigel F. The presence of fistulas and NOD2 homozygosity strongly predict intestinal stenosis in Crohn’s disease independent of the IL23R genotype. J Gastroenterol. 2010;45:721-731. [PMID: 20428899 DOI: 10.1007/s00535-010-0231-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
191 Laharie D, Salzmann M, Boubekeur H, Richy F, Amouretti M, Quinton A, Couzigou P, Lamouliatte H, Zerbib F. Predictors of response to infliximab in luminal Crohn's disease. Gastroenterol Clin Biol 2005;29:145-9. [PMID: 15795662 DOI: 10.1016/s0399-8320(05)80718-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
192 Bonafiglia QA, Lourenssen SR, Hurlbut DJ, Blennerhassett MG. Epigenetic modification of intestinal smooth muscle cell phenotype during proliferation. American Journal of Physiology-Cell Physiology 2018;315:C722-33. [DOI: 10.1152/ajpcell.00216.2018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
193 Gardenbroek TJ, Eshuis EJ, van Acker GJ, Tanis PJ, Bemelman WA. Alternative specimen extraction techniques after laparoscopic emergency colectomy in inflammatory bowel disease. Surg Endosc. 2012;26:408-412. [PMID: 21909858 DOI: 10.1007/s00464-011-1888-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
194 Marcuzzi A, Bianco AM, Girardelli M, Tommasini A, Martelossi S, Monasta L, Crovella S. Genetic and functional profiling of Crohn's disease: autophagy mechanism and susceptibility to infectious diseases. Biomed Res Int 2013;2013:297501. [PMID: 23738324 DOI: 10.1155/2013/297501] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
195 Latella G, Caprilli R, Travis S. In favour of early surgery in Crohn's disease: a hypothesis to be tested. J Crohns Colitis. 2011;5:1-4. [PMID: 21272796 DOI: 10.1016/j.crohns.2010.11.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
196 Cross RK, Wilson KT, Binion DG. Polypharmacy and Crohn’s disease. Aliment Pharmacol Ther. 2005;21:1211-1216. [PMID: 15882241 DOI: 10.1111/j.1365-2036.2005.02429.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
197 Ónody A, Veres-Székely A, Pap D, Rokonay R, Szebeni B, Sziksz E, Oswald F, Veres G, Cseh Á, Szabó AJ, Vannay Á. Interleukin-24 regulates mucosal remodeling in inflammatory bowel diseases. J Transl Med 2021;19:237. [PMID: 34078403 DOI: 10.1186/s12967-021-02890-7] [Reference Citation Analysis]
198 de Bruyn JR, Meijer SL, Wildenberg ME, Bemelman WA, van den Brink GR, D'Haens GR. Development of Fibrosis in Acute and Longstanding Ulcerative Colitis. J Crohns Colitis 2015;9:966-72. [PMID: 26245217 DOI: 10.1093/ecco-jcc/jjv133] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
199 Landsend E, Johnson E, Johannessen HO, Carlsen E. Long-term outcome after intestinal resection for Crohn’s disease. Scand J Gastroenterol. 2006;41:1204-1208. [PMID: 16990206 DOI: 10.1080/00365520600731018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
200 American Society for Gastrointestinal Endoscopy Standards of Practice Committee. , Shergill AK, Lightdale JR, Bruining DH, Acosta RD, Chandrasekhara V, Chathadi KV, Decker GA, Early DS, Evans JA, Fanelli RD, Fisher DA, Fonkalsrud L, Foley K, Hwang JH, Jue TL, Khashab MA, Muthusamy VR, Pasha SF, Saltzman JR, Sharaf R, Cash BD, DeWitt JM. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc 2015; 81: 1101-21. e1-13. [PMID: 25800660 DOI: 10.1016/j.gie.2014.10.030] [Cited by in Crossref: 172] [Cited by in F6Publishing: 139] [Article Influence: 28.7] [Reference Citation Analysis]
201 Chinem ESS, Esberard BC, Moreira ADL, Barbassa TG, da Cunha GM, Carneiro AJV, de Souza HS, Carvalho ATP. Changes in the Management of Patients with Crohn's Disease Based on Magnetic Resonance Enterography Patterns. Gastroenterol Res Pract. 2019;2019:3467316. [PMID: 31933630 DOI: 10.1155/2019/3467316] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
202 Strong SA, Koltun WA, Hyman NH, Buie DW. Practice Parameters for the Surgical Management of Crohn's Disease. Diseases of the Colon & Rectum 2007;50:1735-46. [DOI: 10.1007/s10350-007-9012-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
203 Mendoza JL, Urcelay E, Lana R, Martinez A, Taxonera C, de la Concha EG, Díaz-Rubio M. Polymorphisms in interleukin-10 gene according to mutations of NOD2/CARD15 gene and relation to phenotype in Spanish patients with Crohn's disease. World J Gastroenterol 2006;12:443-8. [PMID: 16489646 DOI: 10.3748/wjg.v12.i3.443] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
204 Gazouli M, Zacharatos P, Mantzaris GJ, Barbatis C, Ikonomopoulos I, Archimandritis AJ, Lukas JC, Papalambros E, Gorgoulis V. Association of NOD2/CARD15 variants with Crohn's disease in a Greek population. Eur J Gastroenterol Hepatol 2004;16:1177-82. [PMID: 15489579 DOI: 10.1097/00042737-200411000-00016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
205 Barros LL, Farias AQ, Rezaie A. Gastrointestinal motility and absorptive disorders in patients with inflammatory bowel diseases: Prevalence, diagnosis and treatment. World J Gastroenterol. 2019;25:4414-4426. [PMID: 31496621 DOI: 10.3748/wjg.v25.i31.4414] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 15] [Article Influence: 22.0] [Reference Citation Analysis]
206 Okabayashi K, Hasegawa H, Watanabe M, Nishibori H, Ishii Y, Hibi T, Kitajima M. Indications for laparoscopic surgery for Crohn’s disease using the Vienna Classification. Colorectal Dis. 2007;9:825-829. [PMID: 17645573 DOI: 10.1111/j.1463-1318.2007.01294.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
207 Aloi M, Viola F, D'Arcangelo G, Di Nardo G, Civitelli F, Casciani E, Oliva S, Nuti F, Dilillo A, Cucchiara S. Disease course and efficacy of medical therapy in stricturing paediatric Crohn's disease. Dig Liver Dis 2013;45:464-8. [PMID: 23465684 DOI: 10.1016/j.dld.2013.01.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
208 Torres Udos S, Rodrigues JO, Junqueira MS, Uezato S, Netinho JG. The Montreal classification for Crohn's disease: clinical application to a Brazilian single-center cohort of 90 consecutive patients. Arq Gastroenterol. 2010;47:279-284. [PMID: 21140090 DOI: 10.1590/s0004-28032010000300013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
209 Griffiths AM. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol. 2004;18:509-523. [PMID: 15157824 DOI: 10.1016/j.bpg.2004.01.002] [Cited by in Crossref: 233] [Cited by in F6Publishing: 197] [Article Influence: 13.7] [Reference Citation Analysis]
210 Aratari A, Papi C, Leandro G, Viscido A, Capurso L, Caprilli R. Early versus late surgery for ileo-caecal Crohn’s disease. Aliment Pharmacol Ther. 2007;26:1303-1312. [PMID: 17848181 DOI: 10.1111/j.1365-2036.2007.03515.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 4.1] [Reference Citation Analysis]
211 Eidelwein AP, Thompson R, Fiorino K, Abadom V, Oliva-Hemker M. Disease presentation and clinical course in black and white children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:555-60. [PMID: 17460486 DOI: 10.1097/MPG.0b013e3180335bb3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
212 Latella G, Papi C. Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol. 2012;18:3790-3799. [PMID: 22876029 DOI: 10.3748/wjg.v18.i29.3790] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 57] [Article Influence: 8.8] [Reference Citation Analysis]
213 Dubinsky MC, Taylor K, Targan SR, Rotter JI. Immunogenetic phenotypes in inflammatory bowel disease. World J Gastroenterol. 2006;12:3645-3650. [PMID: 16773679 DOI: 10.3748/wjg.v12.i23.3645] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
214 Kamm MA, Ng SC, De Cruz P, Allen P, Hanauer SB. Practical application of anti-TNF therapy for luminal Crohn’s disease. Inflamm Bowel Dis. 2011;17:2366-2391. [PMID: 21337669 DOI: 10.1002/ibd.21655] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
215 Walfish A, Sachar D. Phenotype classification in IBD: Is there an impact on therapy?: . Inflammatory Bowel Diseases 2007;13:1573-5. [DOI: 10.1002/ibd.20232] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
216 Armuzzi A, Ahmad T, Ling KL, de Silva A, Cullen S, van Heel D, Orchard TR, Welsh KI, Marshall SE, Jewell DP. Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut 2003;52:1133-9. [PMID: 12865271 DOI: 10.1136/gut.52.8.1133] [Cited by in Crossref: 114] [Cited by in F6Publishing: 102] [Article Influence: 6.3] [Reference Citation Analysis]
217 Plevris N, Fulforth J, Lyons M, Siakavellas SI, Jenkinson PW, Chuah CS, Lucaciu L, Pattenden RJ, Arnott ID, Jones G, Lees CW. Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn’s Disease. Clinical Gastroenterology and Hepatology 2021;19:1835-1844.e6. [DOI: 10.1016/j.cgh.2020.08.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
218 Yap LM, Ahmad T, Jewell DP. The contribution of HLA genes to IBD susceptibility and phenotype. Best Pract Res Clin Gastroenterol. 2004;18:577-596. [PMID: 15157829 DOI: 10.1016/j.bpg.2004.01.003] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis]
219 Magro F, Portela F, Lago P, Ramos de Deus J, Vieira A, Peixe P, Cremers I, Cotter J, Cravo M, Tavares L, Reis J, Gonçalves R, Lopes H, Caldeira P, Ministro P, Carvalho L, Azevedo L, da Costa-Pereira A; GEDII. Crohn's disease in a southern European country: Montreal classification and clinical activity. Inflamm Bowel Dis 2009;15:1343-50. [PMID: 19235885 DOI: 10.1002/ibd.20901] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
220 Chatu S, Subramanian V, Saxena S, Pollok RC. The role of thiopurines in reducing the need for surgical resection in Crohn’s disease: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109:23-34; quiz 35. [PMID: 24322839 DOI: 10.1038/ajg.2013.402] [Cited by in Crossref: 68] [Cited by in F6Publishing: 54] [Article Influence: 8.5] [Reference Citation Analysis]
221 Jiang H, Shen J, Ran Z. Epithelial-mesenchymal transition in Crohn's disease. Mucosal Immunol. 2018;11:294-303. [PMID: 29346350 DOI: 10.1038/mi.2017.107] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
222 Salice M, Rizzello F, Sgambato D, Calabrese C, Manguso F, Laureti S, Rottoli M, Poggioli G, Gionchetti P. Long term remission after ileorectal anastomosis in Crohn's colitis. Digestive and Liver Disease 2021;53:592-7. [DOI: 10.1016/j.dld.2020.06.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
223 Schoepfer AM, Flogerzi B, Seibold-Schmid B, Schaffer T, Kun JF, Pittet V, Mueller S, Seibold F. Low Mannan-binding lectin serum levels are associated with complicated Crohn's disease and reactivity to oligomannan (ASCA). Am J Gastroenterol 2009;104:2508-16. [PMID: 19532127 DOI: 10.1038/ajg.2009.315] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
224 Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn’s disease. Am J Gastroenterol. 2006;101:1030-1038. [PMID: 16606351 DOI: 10.1111/j.1572-0241.2006.00463.x] [Cited by in Crossref: 139] [Cited by in F6Publishing: 120] [Article Influence: 9.3] [Reference Citation Analysis]
225 Yang Q, Gao X, Chen H, Li M, Wu X, Zhi M, Lan P, Hu P. Efficacy of exclusive enteral nutrition in complicated Crohn's disease. Scand J Gastroenterol. 2017;52:995-1001. [PMID: 28598298 DOI: 10.1080/00365521.2017.1335770] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
226 Moon CM, Jung SA, Kim SE, Song HJ, Jung Y, Ye BD, Cheon JH, Kim YS, Kim YH, Kim JS, Han DS; CONNECT study group. Clinical Factors and Disease Course Related to Diagnostic Delay in Korean Crohn's Disease Patients: Results from the CONNECT Study. PLoS One. 2015;10:e0144390. [PMID: 26647084 DOI: 10.1371/journal.pone.0144390] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
227 Jeong SH, Choi JS, Kim JW, Kim HM, Kim HS, Im JP, Kim JS, Kim YS, Cheon JH, Kim WH, Ye BD, Kim YH, Han DS. Clinical Features of Intra-Abdominal Abscess and Intestinal Free-Wall Perforation in Korean Patients with Crohn's Disease: Results from the CONNECT Study. J Clin Med 2020;10:E116. [PMID: 33396251 DOI: 10.3390/jcm10010116] [Reference Citation Analysis]
228 Klebl FH, Bataille F, Huy C, Hofst??dter F, Sch??lmerich J, Rogler G. Association of antibodies to exocrine pancreas with subtypes of Crohn's disease: . European Journal of Gastroenterology & Hepatology 2005;17:73-7. [DOI: 10.1097/00042737-200501000-00015] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
229 Li X, Song P, Li J, Tao Y, Li G, Li X, Yu Z. The Disease Burden and Clinical Characteristics of Inflammatory Bowel Disease in the Chinese Population: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2017;14. [PMID: 28264519 DOI: 10.3390/ijerph14030238] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
230 Everett SM, Hamlin PJ. Evidence-based use of anti-TNFα therapy in Crohn's disease; where are we in 2011? Frontline Gastroenterol 2011;2:144-50. [PMID: 28839599 DOI: 10.1136/fg.2010.003566] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
231 Jiang L, Xia B, Li J, Ye M, Yan W, Deng C, Ding Y, Luo H, Hou W, Zhao Q, Liu N, Ren H, Hou X, Xu H. Retrospective survey of 452 patients with inflammatory bowel disease in Wuhan city, central China. Inflamm Bowel Dis 2006;12:212-7. [PMID: 16534423 DOI: 10.1097/01.MIB.0000201098.26450.ae] [Cited by in Crossref: 107] [Cited by in F6Publishing: 39] [Article Influence: 7.1] [Reference Citation Analysis]
232 Bernstein CN. Does everyone with inflammatory bowel disease need to be treated with combination therapy? Curr Opin Gastroenterol 2016;32:287-93. [PMID: 27115220 DOI: 10.1097/MOG.0000000000000281] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
233 Liu B, Gulati AS, Cantillana V, Henry SC, Schmidt EA, Daniell X, Grossniklaus E, Schoenborn AA, Sartor RB, Taylor GA. Irgm1-deficient mice exhibit Paneth cell abnormalities and increased susceptibility to acute intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 2013;305:G573-84. [PMID: 23989005 DOI: 10.1152/ajpgi.00071.2013] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 9.3] [Reference Citation Analysis]
234 De la Fuente M, Franchi L, Araya D, Díaz-Jiménez D, Olivares M, Álvarez-Lobos M, Golenbock D, González MJ, López-Kostner F, Quera R, Núñez G, Vidal R, Hermoso MA. Escherichia coli isolates from inflammatory bowel diseases patients survive in macrophages and activate NLRP3 inflammasome. Int J Med Microbiol 2014;304:384-92. [PMID: 24581881 DOI: 10.1016/j.ijmm.2014.01.002] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 7.0] [Reference Citation Analysis]
235 Takeda T, Kishi M, Takatsu N, Takada Y, Beppu T, Miyaoka M, Hisabe T, Ueki T, Arima H, Hirai F, Yao K. Long-term outcomes of endoscopic balloon dilation for intestinal strictures in patients with Crohn's disease during maintenance treatment with anti-tumor necrosis factor alpha antibodies. Dig Endosc 2021. [PMID: 34185921 DOI: 10.1111/den.14073] [Reference Citation Analysis]
236 Maehata Y, Nagata Y, Moriyama T, Matsuno Y, Hirano A, Umeno J, Torisu T, Manabe T, Kitazono T, Esaki M. Risk of surgery in patients with stricturing type of Crohn's disease at the initial diagnosis: a single center experience. Intest Res 2019;17:357-64. [PMID: 30781932 DOI: 10.5217/ir.2018.00107] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
237 Louis E, Belaiche J, Reenaers C. Are we giving biologics too much time? When should we stop treatment? WJG 2008;14:5528. [DOI: 10.3748/wjg.14.5528] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
238 Vester-Andersen MK, Prosberg MV, Jess T, Andersson M, Bengtsson BG, Blixt T, Munkholm P, Bendtsen F, Vind I. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gastroenterol. 2014;109:705-714. [PMID: 24642581 DOI: 10.1038/ajg.2014.45] [Cited by in Crossref: 111] [Cited by in F6Publishing: 97] [Article Influence: 15.9] [Reference Citation Analysis]
239 Gasche C, Alizadeh BZ, Peña AS. Genotype–phenotype correlations: how many disorders constitute inflammatory bowel disease? European Journal of Gastroenterology & Hepatology 2003;15:599-606. [DOI: 10.1097/00042737-200306000-00004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
240 Gasche C, Grundtner P. Genotypes and phenotypes in Crohn's disease: do they help in clinical management? Gut 2005;54:162-7. [PMID: 15591523 DOI: 10.1136/gut.2003.035600] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
241 Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut. 2004;53:1117-1122. [PMID: 15247177 DOI: 10.1136/gut.2003.030734] [Cited by in Crossref: 88] [Cited by in F6Publishing: 85] [Article Influence: 5.2] [Reference Citation Analysis]
242 Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, Fell J, Ruemmele FM, Walters T, Sherlock M, Dubinsky M, Hyams JS. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314-1321. [PMID: 21560194 DOI: 10.1002/ibd.21493] [Cited by in Crossref: 789] [Cited by in F6Publishing: 659] [Article Influence: 71.7] [Reference Citation Analysis]
243 Gupta N, Bostrom AG, Kirschner BS, Ferry GD, Gold BD, Cohen SA, Winter HS, Baldassano RN, Abramson O, Smith T. Incidence of stricturing and penetrating complications of Crohn’s disease diagnosed in pediatric patients. Inflamm Bowel Dis. 2010;16:638-644. [PMID: 19760783 DOI: 10.1002/ibd.21099] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
244 Seiderer J, Brand S, Herrmann KA, Schnitzler F, Hatz R, Crispin A, Pfennig S, Schoenberg SO, Göke B, Lohse P, Ochsenkühn T. Predictive value of the CARD15 variant 1007fs for the diagnosis of intestinal stenoses and the need for surgery in Crohnʼs disease in clinical practice: Results of a Prospective Study: . Inflammatory Bowel Diseases 2006;12:1114-21. [DOI: 10.1097/01.mib.0000235836.32176.5e] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 4.7] [Reference Citation Analysis]
245 Wolters FL, Joling C, Russel MG, Sijbrandij J, De Bruin M, Odes S, Riis L, Munkholm P, Bodini P, Ryan B. Treatment inferred disease severity in Crohn's disease: evidence for a European gradient of disease course. Scand J Gastroenterol. 2007;42:333-344. [PMID: 17354113 DOI: 10.1080/00365520600930750] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
246 Schoepfer AM, Schaffer T, Mueller S, Flogerzi B, Vassella E, Seibold-Schmid B, Seibold F. Phenotypic associations of Crohn’s disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss Cohort. Inflamm Bowel Dis. 2009;15:1358-1367. [PMID: 19253375 DOI: 10.1002/ibd.20892] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
247 Ng SC, Bernstein CN, Vatn MH, Lakatos PL, Loftus EV, Tysk C, O’Morain C, Moum B, Colombel JF. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut. 2013;62:630-649. [PMID: 23335431 DOI: 10.1007/s11894-013-0313-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
248 Rieder F, Kugathasan S. Circulating antibodies against bacterial wall products: are there arguments for early immunosuppression? Dig Dis. 2012;30 Suppl 3:55-66. [PMID: 23295693 DOI: 10.1159/000342603] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
249 Li G, Ren J, Hu Q, Deng Y, Chen G, Guo K, Li R, Li Y, Wu L, Wang G, Gu G, Li J. Oral pirfenidone protects against fibrosis by inhibiting fibroblast proliferation and TGF-β signaling in a murine colitis model. Biochemical Pharmacology 2016;117:57-67. [DOI: 10.1016/j.bcp.2016.08.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
250 Connelly TM. Predictors of recurrence of Crohn’s disease after ileocolectomy: A review. WJG 2014;20:14393. [DOI: 10.3748/wjg.v20.i39.14393] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
251 Rubin DT, Hanauer SB, Lichtenstein GR, Mcgovern DPB, Regueiro MD, Snapper S, Targan S. Refining Treatment Paradigms in Inflammatory Bowel Disease: Assessing the Options for Individualized Therapy. Am J Gastroenterol Suppl 2016;3:4-7. [DOI: 10.1038/ajgsup.2016.15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
252 Lichtenstein GR, Hanauer SB, Kane SV, Present DH. Crohn’s Is Not a 6-Week Disease: Lifelong Management of Mild to Moderate Crohn’s Disease. Inflammatory Bowel Diseases 2004;10:S2-S10. [DOI: 10.1097/00054725-200407002-00002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
253 Rieder F, Karrasch T, Ben-horin S, Schirbel A, Ehehalt R, Wehkamp J, de Haar C, Velin D, Latella G, Scaldaferri F, Rogler G, Higgins P, Sans M. Results of the 2nd Scientific Workshop of the ECCO (III): Basic mechanisms of intestinal healing. Journal of Crohn's and Colitis 2012;6:373-85. [DOI: 10.1016/j.crohns.2011.11.009] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
254 Louis E, Reenaers C, Belaiche J. Does the phenotype at diagnosis (e.g., fibrostenosing, inflammatory, perforating) predict the course of Crohnʼs disease?: . Inflammatory Bowel Diseases 2008;14:S59-60. [DOI: 10.1097/00054725-200810001-00031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
255 Sorrentino D. Role of biologics and other therapies in stricturing Crohn's disease: what have we learnt so far? Digestion. 2008;77:38-47. [PMID: 18285676 DOI: 10.1159/000117306] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
256 Mahid SS, Mulhall AM, Gholson RD, Eichenberger MR, Galandiuk S. Inflammatory bowel disease and African Americans: a systematic review. Inflamm Bowel Dis 2008;14:960-7. [PMID: 18266229 DOI: 10.1002/ibd.20389] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
257 Choung RS, Princen F, Stockfisch TP, Torres J, Maue AC, Porter CK, Leon F, De Vroey B, Singh S, Riddle MS, Murray JA, Colombel JF; PREDICTS Study Team. Serologic microbial associated markers can predict Crohn's disease behaviour years before disease diagnosis. Aliment Pharmacol Ther 2016;43:1300-10. [PMID: 27117843 DOI: 10.1111/apt.13641] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 10.8] [Reference Citation Analysis]
258 Fu YT, Hong T, Round A, Bressler B. Impact of medical therapy on patients with Crohn's disease requiring surgical resection. World J Gastroenterol 2014;20:11808-14. [PMID: 25206286 DOI: 10.3748/wjg.v20.i33.11808] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
259 Dassopoulos T, Frangakis C, Cruz-Correa M, Talor MV, Burek CL, Datta L, Nouvet F, Bayless TM, Brant SR. Antibodies to saccharomyces cerevisiae in Crohn's disease: higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease. Inflamm Bowel Dis 2007;13:143-51. [PMID: 17206688 DOI: 10.1002/ibd.20031] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
260 Russell RK, Wilson DC, Satsangi J. CARD 15 / NOD 2 in Paediatric Onset Crohn’s Disease: . Journal of Pediatric Gastroenterology and Nutrition 2004;39:216. [DOI: 10.1097/00005176-200408000-00024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
261 Dorn SD, Abad JF, Panagopoulos G, Korelitz BI. Clinical characteristics of familial versus sporadic Crohn‘s disease using the Vienna Classification. Inflamm Bowel Dis. 2004;10:201-206. [PMID: 15290912 DOI: 10.1097/00054725-200405000-00004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
262 Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology. 2010;139:1147-1155. [PMID: 20637205 DOI: 10.1053/j.gastro.2010.06.070] [Cited by in Crossref: 388] [Cited by in F6Publishing: 326] [Article Influence: 35.3] [Reference Citation Analysis]
263 Kim B, Cheon JH, Moon HJ, Park YR, Ye BD, Yang SK, Seo GS, Jang BI, Kim YS, Kim JS, Han DS, Kim YH, Kim WH. Crohn's disease prognosis and early immunomodulator therapy: Results from the CONNECT study. J Gastroenterol Hepatol 2016;31:126-32. [PMID: 26406334 DOI: 10.1111/jgh.13169] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
264 Seiderer J, Schnitzler F, Brand S, Staudinger T, Pfennig S, Herrmann K, Hofbauer K, Dambacher J, Tillack C, Sackmann M. Homozygosity for the CARD15 frameshift mutation 1007fs is predictive of early onset of Crohn’s disease with ileal stenosis, entero-enteral fistulas, and frequent need for surgical intervention with high risk of re-stenosis. Scand J Gastroenterol. 2006;41:1421-1432. [PMID: 17101573 DOI: 10.1080/00365520600703900] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
265 Bueno de Mesquita M, Ferrante M, Henckaerts L, Joossens M, Janssens V, Hlavaty T, Pierik M, Joossens S, Van Schuerbeek N, Van Assche G. Clustering of (auto)immune diseases with early-onset and complicated inflammatory bowel disease. Eur J Pediatr. 2009;168:575-583. [PMID: 18670786 DOI: 10.1007/s00431-008-0798-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
266 Lan N, Shen B. Endoscopic Stricturotomy Versus Balloon Dilation in the Treatment of Anastomotic Strictures in Crohn’s Disease. Inflammatory Bowel Diseases 2018;24:897-907. [DOI: 10.1093/ibd/izx085] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 9.3] [Reference Citation Analysis]
267 Lichtenstein GR, Targan SR, Dubinsky MC, Rotter JI, Barken DM, Princen F, Carroll S, Brown M, Stachelski J, Chuang E, Landers CJ, Stempak JM, Singh S, Silverberg MS. Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior. Inflamm Bowel Dis 2011;17:2488-96. [PMID: 21391291 DOI: 10.1002/ibd.21661] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 5.7] [Reference Citation Analysis]
268 Siddique I, Alazmi W, Al-Ali J, Al-Fadli A, Alateeqi N, Memon A, Hasan F. Clinical epidemiology of Crohn’s disease in Arabs based on the Montreal Classification. Inflamm Bowel Dis. 2012;18:1689-1697. [PMID: 21987450 DOI: 10.1002/ibd.21890] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
269 Kim Y, Jeon SR, Choi SM, Kim HG, Lee TH, Cho JH, Jung Y, Kim WJ, Ko BM, Kim JO, Lee JS, Lee MS. Practice patterns and clinical significance of use of capsule endoscopy in suspected and established Crohn's disease. Intest Res 2017;15:467-74. [PMID: 29142514 DOI: 10.5217/ir.2017.15.4.467] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
270 Watanabe Y, Miyoshi N, Fujino S, Takahashi H, Haraguchi N, Hata T, Matsuda C, Yamamoto H, Doki Y, Mori M, Mizushima T. Cumulative Inflammation Could Be a Risk Factor for Intestinal Failure in Crohn's Disease. Dig Dis Sci. 2019;64:2280-2285. [PMID: 30806860 DOI: 10.1007/s10620-019-05553-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
271 Alvarez-Lobos M, Arostegui JI, Sans M, Tassies D, Plaza S, Delgado S, Lacy AM, Pique JM, Yagüe J, Panés J. Crohn’s disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg. 2005;242:693-700. [PMID: 16244543 DOI: 10.1097/01.sla.0000186173.14696.ea] [Cited by in Crossref: 125] [Cited by in F6Publishing: 115] [Article Influence: 7.8] [Reference Citation Analysis]
272 Onali S, Calabrese E, Pallone F. Measuring disease activity in Crohn’s disease. Abdom Imaging 2012;37:927-32. [DOI: 10.1007/s00261-012-9877-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
273 Takenaka K, Kitazume Y, Fujii T, Tsuchiya K, Watanabe M, Ohtsuka K. Objective evaluation for treat to target in Crohn's disease. J Gastroenterol 2020;55:579-87. [PMID: 32130521 DOI: 10.1007/s00535-020-01678-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
274 Cross RK, Jung C, Wasan S, Joshi G, Sawyer R, Roghmann MC. Racial differences in disease phenotypes in patients with Crohn's disease. Inflamm Bowel Dis. 2006;12:192-198. [PMID: 16534420 DOI: 10.1097/01.mib.0000217767.98389.20] [Cited by in Crossref: 40] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
275 D’Haens GR, Fedorak R, Lémann M, Feagan BG, Kamm MA, Cosnes J, Rutgeerts PJ, Marteau P, Travis S, Schölmerich J. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn’s disease. Inflamm Bowel Dis. 2009;15:1599-1604. [PMID: 19653291 DOI: 10.1002/ibd.21034] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 6.3] [Reference Citation Analysis]
276 Schmoyer CJ, Saidman J, Bohl JL, Bierly CL, Kuemmerle JF, Bickston SJ. The Pathogenesis and Clinical Management of Stricturing Crohn Disease. Inflamm Bowel Dis 2021:izab038. [PMID: 33693860 DOI: 10.1093/ibd/izab038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
277 Lee N, Fowler E, Mason S, Lincoln D, Taaffe DR, Radford-smith G. Tumor necrosis factor-? haplotype is strongly associated with bone mineral density in patients with Crohn's disease. J Gastroenterol Hepatol 2007;22:913-9. [DOI: 10.1111/j.1440-1746.2006.04679.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
278 Kawashima K, Ishihara S, Yuki T, Fukuba N, Sonoyama H, Kazumori H, Yamashita N, Tada Y, Kusunoki R, Oka A, Oshima N, Mishima Y, Moriyama I, Kinoshita Y. Fecal Calprotectin More Accurately Predicts Endoscopic Remission of Crohn's Disease than Serological Biomarkers Evaluated Using Balloon-assisted Enteroscopy. Inflamm Bowel Dis 2017;23:2027-34. [PMID: 28817462 DOI: 10.1097/MIB.0000000000001202] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 7.7] [Reference Citation Analysis]
279 Sugi MD, Menias CO, Lubner MG, Bhalla S, Mellnick VM, Kwon MH, Katz DS. CT Findings of Acute Small-Bowel Entities. RadioGraphics 2018;38:1352-69. [DOI: 10.1148/rg.2018170148] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
280 Lan N, Stocchi L, Delaney CP, Hull TL, Shen B. Endoscopic stricturotomy versus ileocolonic resection in the treatment of ileocolonic anastomotic strictures in Crohn’s disease. Gastrointestinal Endoscopy 2019;90:259-68. [DOI: 10.1016/j.gie.2019.01.021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
281 Forni D, Cleynen I, Ferrante M, Cassinotti A, Cagliani R, Ardizzone S, Vermeire S, Fichera M, Lombardini M, Maconi G. ABO histo-blood group might modulate predisposition to Crohn's disease and affect disease behavior. J Crohns Colitis. 2014;8:489-494. [PMID: 24268527 DOI: 10.1016/j.crohns.2013.10.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
282 Fadda MA, Peedikayil MC, Kagevi I, Kahtani KA, Ben AA, Al HI, Sohaibani FA, Quaiz MA, Abdulla M, Khan MQ. Inflammatory bowel disease in Saudi Arabia: a hospital-based clinical study of 312 patients. Ann Saudi Med. 2012;32:276-282. [PMID: 22588439 DOI: 10.5144/0256-4947] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
283 Tarrant KM, Barclay ML, Frampton CM, Gearry RB. Perianal disease predicts changes in Crohn’s disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol. 2008;103:3082-3093. [PMID: 19086959 DOI: 10.1111/j.1572-0241.2008.02212.x] [Cited by in Crossref: 153] [Cited by in F6Publishing: 138] [Article Influence: 12.8] [Reference Citation Analysis]
284 Echarri A, Ollero V, Barreiro-de Acosta M, Fernández-villaverde A, Hernández V, Lorenzo A, Pereira S, Carpio D, Castro J. Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn’s disease: predictors of efficacy in clinical practice. European Journal of Gastroenterology & Hepatology 2015;27:430-5. [DOI: 10.1097/meg.0000000000000296] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
285 Lopez-Siles M, Aldeguer X, Sabat-Mir M, Serra-Pagès M, Duncan SH, Flint HJ, Garcia-Gil LJ, Martinez-Medina M. Evaluation of bacterial biomarkers to aid in challenging inflammatory bowel diseases diagnostics and subtype classification. World J Gastrointest Pathophysiol 2020;11:64-77. [PMID: 32435523 DOI: 10.4291/wjgp.v11.i3.64] [Reference Citation Analysis]
286 Maggiori L, Panis Y. Surgical management of IBD--from an open to a laparoscopic approach. Nat Rev Gastroenterol Hepatol. 2013;10:297-306. [PMID: 23419288 DOI: 10.1038/nrgastro.2013.30] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
287 Armbruster NS, Stange EF, Wehkamp J. In the Wnt of Paneth Cells: Immune-Epithelial Crosstalk in Small Intestinal Crohn's Disease. Front Immunol 2017;8:1204. [PMID: 29018451 DOI: 10.3389/fimmu.2017.01204] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
288 Rieder F, Reinisch W. Thiopurines and the Natural Course of Crohn's Disease: Did We Finally Find the Right Therapeutic Target? American Journal of Gastroenterology 2014;109:1037-40. [DOI: 10.1038/ajg.2014.162] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
289 Hommes DW. Risks and benefits of biologic therapy for IBD. J Pediatr Gastroenterol Nutr 2009;48 Suppl 2:S52-3. [PMID: 19300125 DOI: 10.1097/MPG.0b013e3181a11785] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
290 Kopylov U, Ben-Horin S, Zmora O, Eliakim R, Katz LH. Anti-tumor necrosis factor and postoperative complications in Crohn’s disease: systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18:2404-2413. [PMID: 22467533 DOI: 10.1002/ibd.22954] [Cited by in Crossref: 125] [Cited by in F6Publishing: 97] [Article Influence: 13.9] [Reference Citation Analysis]
291 Ditrich F, Blümel S, Biedermann L, Fournier N, Rossel JB, Ellinghaus D, Franke A, Stange EF, Rogler G, Scharl M; Swiss IBD Cohort Study Group. Genetic risk factors predict disease progression in Crohn's disease patients of the Swiss inflammatory bowel disease cohort. Therap Adv Gastroenterol 2020;13:1756284820959252. [PMID: 33281934 DOI: 10.1177/1756284820959252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
292 Ostaff MJ, Stange EF, Wehkamp J. Antimicrobial peptides and gut microbiota in homeostasis and pathology. EMBO Mol Med. 2013;5:1465-1483. [PMID: 24039130 DOI: 10.1002/emmm.201201773] [Cited by in Crossref: 171] [Cited by in F6Publishing: 138] [Article Influence: 21.4] [Reference Citation Analysis]
293 Burisch J, Jess T, Martinato M, Lakatos PL; ECCO -EpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7:322-337. [PMID: 23395397 DOI: 10.1016/j.crohns.2013.01.010] [Cited by in Crossref: 541] [Cited by in F6Publishing: 445] [Article Influence: 67.6] [Reference Citation Analysis]
294 Paparo F, Bacigalupo L, Garello I, Biscaldi E, Cimmino MA, Marinaro E, Rollandi GA. Crohn’s disease: prevalence of intestinal and extraintestinal manifestations detected by computed tomography enterography with water enema. Abdom Imaging. 2012;37:326-337. [PMID: 22160373 DOI: 10.1007/s00261-011-9832-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
295 Arulanandan A, Dulai PS, Singh S, Sandborn WJ, Kalmaz D. Systematic review: Safety of balloon assisted enteroscopy in Crohn's disease. World J Gastroenterol. 2016;22:8999-9011. [PMID: 27833391 DOI: 10.3748/wjg.v22.i40.8999] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
296 Fan R, Zhong J, Wang ZT, Li SY, Zhou J, Tang YH. Evaluation of "top-down" treatment of early Crohn's disease by double balloon enteroscopy. World J Gastroenterol 2014;20:14479-87. [PMID: 25339835 DOI: 10.3748/wjg.v20.i39.14479] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
297 van Haaften WT, Blokzijl T, Hofker HS, Olinga P, Dijkstra G, Bank RA, Boersema M. Intestinal stenosis in Crohn's disease shows a generalized upregulation of genes involved in collagen metabolism and recognition that could serve as novel anti-fibrotic drug targets. Therap Adv Gastroenterol 2020;13:1756284820952578. [PMID: 32922514 DOI: 10.1177/1756284820952578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
298 Makharia GK. Quality of care in Crohn's disease. World J Gastrointest Pathophysiol 2014;5:462-6. [PMID: 25400990 DOI: 10.4291/wjgp.v5.i4.462] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
299 Rao BB, Click BH, Koutroubakis IE, Ramos Rivers C, Regueiro M, Swoger J, Schwartz M, Hashash J, Barrie A, Dunn MA, Binion DG. The Cost of Crohn's Disease: Varied Health Care Expenditure Patterns Across Distinct Disease Trajectories. Inflamm Bowel Dis 2017;23:107-15. [PMID: 27930405 DOI: 10.1097/MIB.0000000000000977] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
300 Saadah OI. Childhood onset of Crohn disease: experience from a university teaching hospital in Saudi Arabia. Ann Saudi Med. 2012;32:596-602. [PMID: 23396023 DOI: 10.5144/0256-4947.2012.596] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
301 Mueller T, Rieder B, Bechtner G, Pfeiffer A. The response of Crohn’s strictures to endoscopic balloon dilation. Alimentary Pharmacology & Therapeutics 2010;31:634-9. [DOI: 10.1111/j.1365-2036.2009.04225.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 5.6] [Reference Citation Analysis]
302 Gallego JC, Echarri A. Is there a role of magnetic resonance imaging in deciding to stop anti-tumor necrosis factor treatment in ileal Crohn's disease? Clin Imaging 2017;43:175-9. [PMID: 28334618 DOI: 10.1016/j.clinimag.2017.03.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
303 Lunder AK, Jahnsen J, Bakstad LT, Borthne A, Hov JR, Vatn M, Negård A, Moum B, Solberg IC, Bernklev T, Høie O, Henriksen M, Høivik ML, Hovde Ø, Huppertz-hauss G, Monstad I. Bowel Damage in Patients With Long-term Crohn’s Disease, Assessed by Magnetic Resonance Enterography and the Lémann Index. Clinical Gastroenterology and Hepatology 2018;16:75-82.e5. [DOI: 10.1016/j.cgh.2017.06.053] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
304 Wolters FL, Russel MG, Sijbrandij J, Ambergen T, Odes S, Riis L, Langholz E, Politi P, Qasim A, Koutroubakis I. Phenotype at diagnosis predicts recurrence rates in Crohn’s disease. Gut. 2006;55:1124-1130. [PMID: 16361306 DOI: 10.1136/gut.2005.084061] [Cited by in Crossref: 160] [Cited by in F6Publishing: 140] [Article Influence: 10.0] [Reference Citation Analysis]
305 Huang JG, Aw MM. Pediatric Inflammatory Bowel Disease in Asia: Epidemiology and natural history. Pediatr Neonatol 2020;61:263-71. [PMID: 32005607 DOI: 10.1016/j.pedneo.2019.12.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
306 Lopez-siles M, Martinez-medina M, Busquets D, Sabat-mir M, Duncan SH, Flint HJ, Aldeguer X, Garcia-gil LJ. Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish Irritable Bowel Syndrome and Inflammatory Bowel Disease phenotypes. International Journal of Medical Microbiology 2014;304:464-75. [DOI: 10.1016/j.ijmm.2014.02.009] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 9.4] [Reference Citation Analysis]
307 Prideaux L, De Cruz P, Ng SC, Kamm MA. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2012;18:1340-1355. [PMID: 22069240 DOI: 10.1002/ibd.21903] [Cited by in Crossref: 111] [Cited by in F6Publishing: 85] [Article Influence: 11.1] [Reference Citation Analysis]
308 Rinawi F, Assa A, Hartman C, Mozer Glassberg Y, Nachmias Friedler V, Rosenbach Y, Silbermintz A, Zevit N, Shamir R. Evolution of disease phenotype in pediatric-onset Crohn’s disease after more than 10 years follow up—Cohort study. Digestive and Liver Disease 2016;48:1444-50. [DOI: 10.1016/j.dld.2016.08.118] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
309 Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn’s disease. World J Gastroenterol. 2012;18:4823-4854. [PMID: 23002356 DOI: 10.3748/wjg.v18.i35.4823] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
310 Nishida Y, Hosomi S, Yamagami H, Yukawa T, Nagami Y, Tanaka F, Kamata N, Tanigawa T, Shiba M, Watanabe T, Tominaga K, Fujiwara Y, Arakawa T. Analysis of the Risk Factors of Surgery after Endoscopic Balloon Dilation for Small Intestinal Strictures in Crohn's Disease Using Double-balloon Endoscopy. Intern Med 2017;56:2245-52. [PMID: 28794359 DOI: 10.2169/internalmedicine.8224-16] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
311 Schulz C, Mönkemüller K, Salheiser M, Bellutti M, Schütte K, Malfertheiner P. Double-balloon enteroscopy in the diagnosis of suspected isolated Crohn’s disease of the small bowel. Dig Endosc. 2014;26:236-242. [PMID: 23855454 DOI: 10.1111/den.12142] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
312 Goetz M, Neurath MF. Imaging techniques in inflammatory bowel disease: recent trends, questions and answers. Gastroenterol Clin Biol. 2009;33 Suppl 3:S174-S182. [PMID: 20117340 DOI: 10.1016/s0399-8320(09)73152-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
313 Santana GO, Souza LR, Azevedo M, Sá AC, Bastos CM, Lyra AC. Application of the Vienna classification for Crohn's disease to a single center from Brazil. Arq Gastroenterol 2008;45:64-8. [PMID: 18425231 DOI: 10.1590/s0004-28032008000100012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
314 Allen PB, De Cruz P, Lee WK, Taylor S, Desmond PV, Kamm MA. Noninvasive imaging of the small bowel in Crohnʼs disease: The final frontier: . Inflammatory Bowel Diseases 2011;17:1987-99. [DOI: 10.1002/ibd.21598] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
315 Uno Y. Hypothesis: Mechanism of irritable bowel syndrome in inflammatory bowel disease. Med Hypotheses 2019;132:109324. [PMID: 31421429 DOI: 10.1016/j.mehy.2019.109324] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
316 Rieder F, Fiocchi C, Rogler G. Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases. Gastroenterology. 2017;152:340-350.e6. [PMID: 27720839 DOI: 10.1053/j.gastro.2016.09.047] [Cited by in Crossref: 163] [Cited by in F6Publishing: 135] [Article Influence: 32.6] [Reference Citation Analysis]
317 Wang J, Ortiz C, Fontenot L, Xie Y, Ho W, Mattai SA, Shih DQ, Koon HW. High circulating elafin levels are associated with Crohn's disease-associated intestinal strictures. PLoS One 2020;15:e0231796. [PMID: 32287314 DOI: 10.1371/journal.pone.0231796] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
318 Chow DK, Sung JJ, Wu JC, Tsoi KK, Leong RW, Chan FK. Upper gastrointestinal tract phenotype of Crohn's disease is associated with early surgery and further hospitalization. Inflamm Bowel Dis. 2009;15:551-557. [PMID: 19067420 DOI: 10.1002/ibd.20804] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
319 Rutgeerts P. How to Guide Therapeutic Decisions in a Patient-Tailored Approach to Treatment of IBD? Dig Dis 2012;30:396-9. [DOI: 10.1159/000338137] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
320 Di Sabatino A, Ciccocioppo R, Armellini E, Morera R, Ricevuti L, Cazzola P, Fulle I, Corazza GR. Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn’s disease. Inflamm Bowel Dis. 2004;10:573-577. [PMID: 15472517 DOI: 10.1097/00054725-200409000-00011] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 3.4] [Reference Citation Analysis]
321 Allocca M, Furfaro F, Fiorino G, Peyrin-Biroulet L, Danese S. Point-of-Care Ultrasound in Inflammatory Bowel Disease. J Crohns Colitis 2021;15:143-51. [PMID: 32674146 DOI: 10.1093/ecco-jcc/jjaa151] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
322 Holleran G, Valerii G, Tortora A, Scaldaferri F, Conti S, Amato A, Gasbarrini A, Costamagna G, Riccioni ME. The use of single balloon enteroscopy in Crohn's disease and its impact on clinical outcome. Scand J Gastroenterol. 2018;53:925-929. [PMID: 29966446 DOI: 10.1080/00365521.2018.1476914] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
323 Subramanian S, Ekbom A, Rhodes JM. Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD? Gut. 2017;66:362-381. [PMID: 27802156 DOI: 10.1136/gutjnl-2016-312673] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
324 Lin SN, Zheng DP, Qiu Y, Zhang SH, He Y, Chen BL, Zeng ZR, Mao R, Chen MH. Classifying Crohn's disease into colon-involving versus non-colon-involving groups is a better predictor of clinical outcomes than the Montreal classification. Therap Adv Gastroenterol 2020;13:1756284820968732. [PMID: 33329758 DOI: 10.1177/1756284820968732] [Reference Citation Analysis]
325 Panaccione R, Colombel JF, Sandborn WJ, Rutgeerts P, D’Haens GR, Robinson AM, Chao J, Mulani PM, Pollack PF. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease. Aliment Pharmacol Ther. 2010;31:1296-1309. [PMID: 20298496 DOI: 10.1111/j.1365-2036.2010.04304.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 56] [Article Influence: 6.1] [Reference Citation Analysis]
326 Bayart P, Duveau N, Nachury M, Zerbib P, Gerard R, Branche J, Maunoury V, Wils P, Boruchowicz A, Boualit M, Laberenne J, Manolache O, Desreumaux P, de Chambrun GP, Pariente B. Ileal or Anastomotic Location of Lesions Does Not Impact Rate of Postoperative Recurrence in Crohn’s Disease Patients Classified i2 on the Rutgeerts Score. Dig Dis Sci 2016;61:2986-92. [DOI: 10.1007/s10620-016-4215-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
327 Kadir S, Wenzel Kragstrup T, Dige A, Kok Jensen S, Dahlerup JF, Kelsen J. Pirfenidone inhibits the proliferation of fibroblasts from patients with active Crohn’s disease. Scandinavian Journal of Gastroenterology 2016;51:1321-5. [DOI: 10.1080/00365521.2016.1185146] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
328 Vrabie R, Irwin GL, Friedel D. Endoscopic management of inflammatory bowel disease strictures. World J Gastrointest Endosc. 2012;4:500-505. [PMID: 23189221 DOI: 10.4253/wjge.v4.i11.500] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
329 Bhagya Rao B, Koutroubakis IE, Ramos Rivers C, Colombel JF, Regueiro M, Swoger J, Schwartz M, Baidoo L, Hashash J, Barrie A, Dunn MA, Binion DG. Delineation of Crohn’s Disease Trajectories Using Change in Lémann Index: A Natural History Study. Journal of Clinical Gastroenterology 2016;50:476-82. [DOI: 10.1097/mcg.0000000000000463] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
330 Gutiérrez A, Holler E, Zapater P, Sempere L, Jover R, Pérez-Mateo M, Schoelmerich J, Such J, Wiest R, Francés R. Antimicrobial peptide response to blood translocation of bacterial DNA in Crohn's disease is affected by NOD2/CARD15 genotype. Inflamm Bowel Dis 2011;17:1641-50. [PMID: 21744420 DOI: 10.1002/ibd.21537] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
331 Schreiber S, Reinisch W, Colombel JF, Sandborn WJ, Hommes DW, Robinson AM, Huang B, Lomax KG, Pollack PF. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis. 2013;7:213-221. [PMID: 22704916 DOI: 10.1016/j.crohns.2012.05.015] [Cited by in Crossref: 97] [Cited by in F6Publishing: 82] [Article Influence: 10.8] [Reference Citation Analysis]
332 Wibmer AG, Kroesen AJ, Gröne J, Buhr HJ, Ritz JP. Comparison of strictureplasty and endoscopic balloon dilatation for stricturing Crohn’s disease--review of the literature. Int J Colorectal Dis. 2010;25:1149-1157. [PMID: 20628881 DOI: 10.1007/s00384-010-1010-x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 5.6] [Reference Citation Analysis]
333 Kim DH, Carucci LR, Baker ME, Cash BD, Dillman JR, Feig BW, Fowler KJ, Gage KL, Noto RB, Smith MP, Yaghmai V, Yee J, Lalani T. ACR Appropriateness Criteria Crohn Disease. J Am Coll Radiol 2015;12:1048-57.e4. [PMID: 26435118 DOI: 10.1016/j.jacr.2015.07.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 6.6] [Reference Citation Analysis]
334 Sinh P, Shen B. Endoscopic evaluation of surgically altered bowel in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2015;21:1459-71. [PMID: 25806847 DOI: 10.1097/MIB.0000000000000357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
335 Law S, Li KK. Age-related differences in the clinical course of Crohn’s disease in an asian population: A retrospective cohort review. Indian Pediatr 2013;50:1148-52. [DOI: 10.1007/s13312-013-0301-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
336 Thia KT, Luman W, Jin OC. Crohn’s disease runs a more aggressive course in young Asian patients. Inflamm Bowel Dis. 2006;12:57-61. [PMID: 16374260 DOI: 10.1097/01.MIB.0000195390.11645.7d] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
337 Sorrentino D, Nguyen VQ, Chitnavis MV. Capturing the Biologic Onset of Inflammatory Bowel Diseases: Impact on Translational and Clinical Science. Cells 2019;8:E548. [PMID: 31174359 DOI: 10.3390/cells8060548] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
338 Actis GC, Pellicano R. Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment. World J Gastrointest Pharmacol Ther 2017;8:114-9. [PMID: 28533920 DOI: 10.4292/wjgpt.v8.i2.114] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
339 Pierre N, Salée C, Massot C, Blétard N, Mazzucchelli G, Smargiasso N, Morsa D, Baiwir D, De Pauw E, Reenaers C, Van Kemseke C, Loly J, Delvenne P, Meuwis M, Louis E. Proteomics Highlights Common and Distinct Pathophysiological Processes Associated with Ileal and Colonic Ulcers in Crohn’s Disease. Journal of Crohn's and Colitis 2020;14:205-15. [DOI: 10.1093/ecco-jcc/jjz130] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
340 Lo B, Vester-Andersen MK, Vind I, Prosberg M, Dubinsky M, Siegel CA, Bendtsen F, Burisch J. Changes in Disease Behaviour and Location in Patients With Crohn's Disease After Seven Years of Follow-Up: A Danish Population-based Inception Cohort. J Crohns Colitis. 2018;12:265-272. [PMID: 29506105 DOI: 10.1093/ecco-jcc/jjx138] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
341 Pavlovic-Calic N, Salkic NN, Gegic A, Smajic M, Alibegovic E. Crohn's disease in Tuzla region of Bosnia and Herzegovina: a 12-year study (1995-2006). Int J Colorectal Dis. 2008;23:957-964. [PMID: 18548259 DOI: 10.1007/s00384-008-0493-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
342 Rieder F, Paul G, Schnoy E, Schleder S, Wolf A, Kamm F, Dirmeier A, Strauch U, Obermeier F, Lopez R, Achkar JP, Rogler G, Klebl F. Hemoglobin and hematocrit levels in the prediction of complicated Crohn's disease behavior--a cohort study. PLoS One 2014;9:e104706. [PMID: 25116048 DOI: 10.1371/journal.pone.0104706] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
343 Bernstein CN, Greenberg H, Boult I, Chubey S, Leblanc C, Ryner L. A prospective comparison study of MRI versus small bowel follow-through in recurrent Crohn's disease. Am J Gastroenterol 2005;100:2493-502. [PMID: 16279905 DOI: 10.1111/j.1572-0241.2005.00239.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 65] [Article Influence: 4.9] [Reference Citation Analysis]
344 Lovasz BD, Lakatos L, Horvath A, Szita I, Pandur T, Mandel M, Vegh Z, Golovics PA, Mester G, Balogh M, Molnar C, Komaromi E, Kiss LS, Lakatos PL. Evolution of disease phenotype in adult and pediatric onset Crohn's disease in a population-based cohort. World J Gastroenterol. 2013;19:2217-2226. [PMID: 23599648 DOI: 10.3748/wjg.v19.i14.2217] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 36] [Article Influence: 5.5] [Reference Citation Analysis]
345 Silverman J, Otley A. Budesonide in the treatment of inflammatory bowel disease. Expert Rev Clin Immunol. 2011;7:419-428. [PMID: 21790284 DOI: 10.1586/eci.11.34] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
346 Park JJ, Yang SK, Ye BD, Kim JW, Park DI, Yoon H, Im JP, Lee KM, Yoon SN, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. [Second Korean Guidelines for the Management of Crohn's Disease]. Korean J Gastroenterol 2017;69:29-54. [PMID: 28135790 DOI: 10.4166/kjg.2017.69.1.29] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
347 Rimola J, Panés J, Ordás I. Magnetic resonance enterography in Crohn's disease: optimal use in clinical practice and clinical trials. Scand J Gastroenterol 2015;50:66-73. [PMID: 25523557 DOI: 10.3109/00365521.2014.968862] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
348 Bettenworth D, Nowacki TM, Cordes F, Buerke B, Lenze F. Assessment of stricturing Crohn's disease: Current clinical practice and future avenues. World J Gastroenterol. 2016;22:1008-1016. [PMID: 26811643 DOI: 10.3748/wjg.v22.i3.1008] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
349 Sachar DB. Recurrence rates in Crohn's disease: predicting the future and predicting the past. Gut 2006;55:1069-70. [PMID: 16849342 DOI: 10.1136/gut.2005.088658] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
350 Makanyanga JC, Taylor SA. Current and future role of MR enterography in the management of Crohn disease. AJR Am J Roentgenol. 2013;201:56-64. [PMID: 23789658 DOI: 10.2214/ajr.12.10406] [Cited by in Crossref: 29] [Cited by in F6Publishing: 9] [Article Influence: 3.6] [Reference Citation Analysis]
351 Targownik LE, Singh H, Nugent Z, Bernstein CN. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol. 2012;107:1228-1235. [PMID: 22613902 DOI: 10.1038/ajg.2012.127] [Cited by in Crossref: 179] [Cited by in F6Publishing: 155] [Article Influence: 19.9] [Reference Citation Analysis]
352 Rieder F, Latella G, Magro F, Yuksel ES, Higgins PDR, Di Sabatino A, de Bruyn JR, Rimola J, Brito J, Bettenworth D, van Assche G, Bemelman W, d’Hoore A, Pellino G, Dignass AU. European Crohn’s and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn’s Disease. ECCOJC 2016;10:873-85. [DOI: 10.1093/ecco-jcc/jjw055] [Cited by in Crossref: 102] [Cited by in F6Publishing: 86] [Article Influence: 20.4] [Reference Citation Analysis]
353 Lakatos PL, Kiss LS. Is the disease course predictable in inflammatory bowel diseases? World J Gastroenterol. 2010;16:2591-2599. [PMID: 20518079 DOI: 10.3748/wjg.v16.i21.2591.] [Reference Citation Analysis]
354 Mazziotti S, Blandino A, Scribano E, Gaeta M, Mileto A, Fries W, Bombaci F, Ascenti G. MR enterography findings in abdominopelvic extraintestinal complications of Crohn's disease. J Magn Reson Imaging 2013;37:1055-63. [DOI: 10.1002/jmri.23859] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
355 Mascheretti S, Schreiber S. Genetic Testing in Crohn Disease: Utility in Individualizing Patient Management. American Journal of PharmacoGenomics 2005;5:213-22. [DOI: 10.2165/00129785-200505040-00002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
356 Wang K, Huang L, Huang W, Liu R, Chen X, Guo Z, Qian W, Yin Y, Li Y, Zhu W. Predictive Value of CT Enterography Index for Postoperative Intra-abdominal Septic Complications in Patients With Crohn's Disease: Implications for Surgical Decision-Making. Dis Colon Rectum 2021;64:964-76. [PMID: 33951684 DOI: 10.1097/DCR.0000000000001796] [Reference Citation Analysis]
357 Armuzzi A, De Pascalis B, Fedeli P, De Vincentis F, Gasbarrini A. Infliximab in Crohn's disease: early and long-term treatment. Digestive and Liver Disease 2008;40:S271-9. [DOI: 10.1016/s1590-8658(08)60537-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
358 Park SH, Aniwan S, Scott Harmsen W, Tremaine WJ, Lightner AL, Faubion WA, Loftus EV. Update on the Natural Course of Fistulizing Perianal Crohn's Disease in a Population-Based Cohort. Inflamm Bowel Dis. 2019;25:1054-1060. [PMID: 30346531 DOI: 10.1093/ibd/izy329] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 29.0] [Reference Citation Analysis]
359 Gerich ME, McGovern DP. Towards personalized care in IBD. Nat Rev Gastroenterol Hepatol. 2014;11:287-299. [PMID: 24345887 DOI: 10.1038/nrgastro.2013.242] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
360 Song WJ, Kang B, Choi SY, Choe YH. Adalimumab Treatment in Pediatric-Onset Crohn's Disease Patients after Infliximab Failure: A Single Center Study. Pediatr Gastroenterol Hepatol Nutr 2016;19:116-22. [PMID: 27437188 DOI: 10.5223/pghn.2016.19.2.116] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
361 Vatn MH, Sandvik AK. Inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2015;50:748-62. [DOI: 10.3109/00365521.2015.1033000] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
362 Hampe J, Grebe J, Nikolaus S, Solberg C, Croucher PJ, Mascheretti S, Jahnsen J, Moum B, Klump B, Krawczak M. Association of NOD2 (CARD 15) genotype with clinical course of Crohn’s disease: a cohort study. Lancet. 2002;359:1661-1665. [PMID: 12020527 DOI: 10.1016/s0140-6736(02)08590-2] [Cited by in Crossref: 290] [Cited by in F6Publishing: 75] [Article Influence: 15.3] [Reference Citation Analysis]
363 Caparrós E, Wiest R, Scharl M, Rogler G, Gutiérrez Casbas A, Yilmaz B, Wawrzyniak M, Francés R. Dysbiotic microbiota interactions in Crohn's disease. Gut Microbes 2021;13:1949096. [PMID: 34313550 DOI: 10.1080/19490976.2021.1949096] [Reference Citation Analysis]
364 Louis E, Belaiche J, Reenaers C. Do clinical factors help to predict disease course in inflammatory bowel disease? World J Gastroenterol. 2010;16:2600-2603. [PMID: 20518080 DOI: 10.3748/wjg.v16.i21.2600] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
365 Bouguen G, Huguet A, Amiot A, Viennot S, Cholet F, Nachury M, Flamant M, Reimund J, Desfourneaux V, Boureille A, Siproudhis L. Efficacy and Safety of Tumor Necrosis Factor Antagonists in Treatment of Internal Fistulizing Crohn's Disease. Clinical Gastroenterology and Hepatology 2020;18:628-36. [DOI: 10.1016/j.cgh.2019.05.027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
366 Heliö T, Halme L, Lappalainen M, Fodstad H, Paavola-Sakki P, Turunen U, Färkkilä M, Krusius T, Kontula K. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn’s disease. Gut. 2003;52:558-562. [PMID: 12631669 DOI: 10.1136/gut.52.4.558] [Cited by in Crossref: 174] [Cited by in F6Publishing: 173] [Article Influence: 9.7] [Reference Citation Analysis]
367 McLarren KW, Cole AE, Weisser SB, Voglmaier NS, Conlin VS, Jacobson K, Popescu O, Boucher JL, Sly LM. SHIP-deficient mice develop spontaneous intestinal inflammation and arginase-dependent fibrosis. Am J Pathol 2011;179:180-8. [PMID: 21640975 DOI: 10.1016/j.ajpath.2011.03.018] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
368 Daperno M, Castiglione F, de Ridder L, Dotan I, Färkkilä M, Florholmen J, Fraser G, Fries W, Hebuterne X, Lakatos PL. Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis. 2011;5:484-498. [PMID: 21939926 DOI: 10.1016/j.crohns.2011.07.003] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 7.2] [Reference Citation Analysis]
369 Halfvarson J, Jess T, Bodin L, Järnerot G, Munkholm P, Binder V, Tysk C. Longitudinal concordance for clinical characteristics in a Swedish-Danish twin population with inflammatory bowel disease. Inflamm Bowel Dis 2007;13:1536-44. [PMID: 17828780 DOI: 10.1002/ibd.20242] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
370 Strong SA. Surgical treatment of inflammatory bowel disease: . Current Opinion in Gastroenterology 2002;18:441-6. [DOI: 10.1097/00001574-200207000-00008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
371 Chatu S, Saxena S, Subramanian V, Curcin V, Yadegarfar G, Gunn L, Majeed A, Pollok RC. The impact of timing and duration of thiopurine treatment on first intestinal resection in Crohn's disease: national UK population-based study 1989-2010. Am J Gastroenterol 2014;109:409-16. [PMID: 24469612 DOI: 10.1038/ajg.2013.462] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
372 Schoepfer AM, Dehlavi MA, Fournier N, Safroneeva E, Straumann A, Pittet V, Peyrin-Biroulet L, Michetti P, Rogler G, Vavricka SR; IBD Cohort Study Group. Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol. 2013;108:1744-1753; quiz 1754. [PMID: 23978953 DOI: 10.1038/ajg.2013.248] [Cited by in Crossref: 117] [Cited by in F6Publishing: 95] [Article Influence: 14.6] [Reference Citation Analysis]
373 Neville JJ, Macdonald A, Fell J, Choudhry M, Haddad M. Therapeutic strategies for stricturing Crohn's disease in childhood: a systematic review. Pediatr Surg Int 2021;37:569-77. [PMID: 33492462 DOI: 10.1007/s00383-020-04848-0] [Reference Citation Analysis]
374 Latella G, Cocco A, Angelucci E, Viscido A, Bacci S, Necozione S, Caprilli R. Clinical course of Crohn’s disease first diagnosed at surgery for acute abdomen. Dig Liver Dis. 2009;41:269-276. [PMID: 18955023 DOI: 10.1016/j.dld.2008.09.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
375 Honzawa Y, Nakase H, Matsuura M, Higuchi H, Toyonaga T, Matsumura K, Yoshino T, Okazaki K, Chiba T. Prior use of immunomodulatory drugs improves the clinical outcome of endoscopic balloon dilation for intestinal stricture in patients with Crohn's disease: Immunomodulation for intestinal stenosis. Digestive Endoscopy 2013;25:535-43. [DOI: 10.1111/den.12029] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
376 Ajlouni Y, Iser JH, Gibson PR. Endoscopic balloon dilatation of intestinal strictures in Crohn's disease: safe alternative to surgery. J Gastroenterol Hepatol. 2007;22:486-490. [PMID: 17376038 DOI: 10.1111/j.1440-1746.2006.04764.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
377 Landerholm K, Reali C, Mortensen NJ, Travis SPL, Guy RJ, George BD. Short- and long-term outcomes of strictureplasty for obstructive Crohn's disease. Colorectal Dis 2020;22:1159-68. [PMID: 32053253 DOI: 10.1111/codi.15013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
378 Targownik LE, Nugent Z, Singh H, Bernstein CN. Prevalence of and Outcomes Associated with Corticosteroid Prescription in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2014;20:622-30. [DOI: 10.1097/mib.0000000000000008] [Cited by in Crossref: 35] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
379 Smids C, Horjus Talabur Horje CS, Drylewicz J, Roosenboom B, Groenen MJM, van Koolwijk E, van Lochem EG, Wahab PJ. Intestinal T Cell Profiling in Inflammatory Bowel Disease: Linking T Cell Subsets to Disease Activity and Disease Course. J Crohns Colitis. 2018;12:465-475. [PMID: 29211912 DOI: 10.1093/ecco-jcc/jjx160] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 13.3] [Reference Citation Analysis]
380 Freeman HJ. Natural history and clinical behavior of Crohn’s disease extending beyond two decades. J Clin Gastroenterol. 2003;37:216-219. [PMID: 12960719 DOI: 10.1097/00004836-200309000-00005] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 4.0] [Reference Citation Analysis]
381 Etchevers MJ, Aceituno M, Sans M. Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. World J Gastroenterol. 2008;14:5512-5518. [PMID: 18810768 DOI: 10.3748/wjg.14.5512] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
382 Thalmaier D, Dambacher J, Seiderer J, Konrad A, Schachinger V, Pfennig S, Otte JM, Crispin A, Göke B, Ochsenkühn T, Lohse P, Brand S. The +1059G/C polymorphism in the C-reactive protein (CRP) gene is associated with involvement of the terminal ileum and decreased serum CRP levels in patients with Crohn's disease. Aliment Pharmacol Ther 2006;24:1105-15. [PMID: 16984505 DOI: 10.1111/j.1365-2036.2006.03093.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
383 Yoon JY, Cheon JH, Park SJ, Kim TI, Kim WH. Effects of Perianal Involvement on Clinical Outcomes in Crohn's Disease over 10 Years. Gut Liver 2018;12:297-305. [PMID: 29108399 DOI: 10.5009/gnl17275] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
384 Lakatos PL, Czegledi Z, Szamosi T, Banai J, David G, Zsigmond F, Pandur T, Erdelyi Z, Gemela O, Papp J. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. World J Gastroenterol. 2009;15:3504-3510. [PMID: 19630105 DOI: 10.3748/wjg.15.3504.] [Reference Citation Analysis]
385 Collyer R, Clancy A, Agrawal G, Borody TJ. Crohn's strictures open with anti-mycobacterial antibiotic therapy: A retrospective review. World J Gastrointest Endosc 2020;12:542-54. [PMID: 33362907 DOI: 10.4253/wjge.v12.i12.542] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
386 de Bruyn JR, Becker MA, Steenkamer J, Wildenberg ME, Meijer SL, Buskens CJ, Bemelman WA, Löwenberg M, Ponsioen CY, van den Brink GR, D'Haens GR. Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease. PLoS One 2018;13:e0190999. [PMID: 29364909 DOI: 10.1371/journal.pone.0190999] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
387 Fernández A, Hernández V, Martínez-Ares D, Sanromán L, de Castro ML, Pineda JR, Carmona A, González-Portela C, Salgado C, Martínez-Cadilla J, Pereira S, García-Burriel JI, Vázquez S, Rodríguez-Prada I; EpiCom Group. Incidence and phenotype at diagnosis of inflammatory bowel disease. Results in Spain of the EpiCom study. Gastroenterol Hepatol 2015;38:534-40. [PMID: 25890448 DOI: 10.1016/j.gastrohep.2015.03.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
388 Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010;105:289-297. [PMID: 19861953 DOI: 10.1038/ajg.2009.579] [Cited by in Crossref: 566] [Cited by in F6Publishing: 483] [Article Influence: 47.2] [Reference Citation Analysis]
389 Pham BT, van Haaften WT, Oosterhuis D, Nieken J, de Graaf IA, Olinga P. Precision-cut rat, mouse, and human intestinal slices as novel models for the early-onset of intestinal fibrosis. Physiol Rep 2015;3:e12323. [PMID: 25907784 DOI: 10.14814/phy2.12323] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
390 Ferrante M, Vermeire S, Rutgeerts P. Certolizumab pegol in the treatment of Crohn's disease. Expert Opinion on Biological Therapy 2013;13:595-605. [DOI: 10.1517/14712598.2013.777039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
391 Taylor SA, Mallett S, Bhatnagar G, Morris S, Quinn L, Tomini F, Miles A, Baldwin-Cleland R, Bloom S, Gupta A, Hamlin PJ, Hart AL, Higginson A, Jacobs I, McCartney S, Murray CD, Plumb AA, Pollok RC, Rodriguez-Justo M, Shabir Z, Slater A, Tolan D, Travis S, Windsor A, Wylie P, Zealley I, Halligan S. Magnetic resonance enterography compared with ultrasonography in newly diagnosed and relapsing Crohn's disease patients: the METRIC diagnostic accuracy study. Health Technol Assess 2019;23:1-162. [PMID: 31432777 DOI: 10.3310/hta23420] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
392 Das K, Ghoshal UC, Dhali GK, Benjamin J, Ahuja V, Makharia GK. Crohn's disease in India: a multicenter study from a country where tuberculosis is endemic. Dig Dis Sci 2009;54:1099-107. [PMID: 18770037 DOI: 10.1007/s10620-008-0469-6] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 4.8] [Reference Citation Analysis]
393 Koelewijn CL, Schwartz MP, Samsom M, Oldenburg B. C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. World J Gastroenterol. 2008;14:85-89. [PMID: 18176967 DOI: 10.3748/wjg.14.85] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
394 Rieder F, Schleder S, Wolf A, Dirmeier A, Strauch U, Obermeier F, Lopez R, Spector L, Fire E, Yarden J. Serum anti-glycan antibodies predict complicated Crohn’s disease behavior: a cohort study. Inflamm Bowel Dis. 2010;16:1367-1375. [PMID: 20024902 DOI: 10.1002/ibd.21179] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 5.5] [Reference Citation Analysis]
395 Elriz K, Palascak-Juif V, Joly F, Seguy D, Beau P, Chambrier C, Boncompain M, Fontaine E, Laharie D, Savoye G, Lerebours E. Crohn's disease patients with chronic intestinal failure receiving long-term parenteral nutrition: a cross-national adult study. Aliment Pharmacol Ther 2011;34:931-40. [PMID: 21848855 DOI: 10.1111/j.1365-2036.2011.04806.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
396 Conte MP, Longhi C, Marazzato M, Conte AL, Aleandri M, Lepanto MS, Zagaglia C, Nicoletti M, Aloi M, Totino V, Palamara AT, Schippa S. Adherent-invasive Escherichia coli (AIEC) in pediatric Crohn's disease patients: phenotypic and genetic pathogenic features. BMC Res Notes. 2014;7:748. [PMID: 25338542 DOI: 10.1186/1756-0500-7-748] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 7.0] [Reference Citation Analysis]
397 Beelen EMJ, van der Woude CJ, Pierik MJ, Hoentjen F, de Boer NK, Oldenburg B, van der Meulen AE, Ponsioen CIJ, Dijkstra G, Bruggink AH, Erler NS, Schouten WR, de Vries AC; Dutch Initiative on Crohn's and Colitis (ICC). Decreasing Trends in Intestinal Resection and Re-Resection in Crohn's Disease: A Nationwide Cohort Study. Ann Surg 2021;273:557-63. [PMID: 31188225 DOI: 10.1097/SLA.0000000000003395] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
398 Banerjee R, Pal P, Girish BG, Reddy DN. Risk factors for diagnostic delay in Crohn's disease and their impact on long-term complications: how do they differ in a tuberculosis endemic region? Aliment Pharmacol Ther 2018;47:1367-74. [DOI: 10.1111/apt.14617] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
399 Mao R, Tang RH, Qiu Y, Chen BL, Guo J, Zhang SH, Li XH, Feng R, He Y, Li ZP, Zeng ZR, Eliakim R, Ben-Horin S, Chen MH. Different clinical outcomes in Crohn's disease patients with esophagogastroduodenal, jejunal, and proximal ileal disease involvement: is L4 truly a single phenotype? Therap Adv Gastroenterol. 2018;11:1756284818777938. [PMID: 29899757 DOI: 10.1177/1756284818777938] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
400 Onal IK, Beyazit Y, Altinbas A, Kurt M, Arhan M. Maintenance therapy for Crohn's disease: should it be indefinite? Eur J Gastroenterol Hepatol. 2015; Jul 15. [Epub ahead of print]. [PMID: 26181109 DOI: 10.1097/MEG.0000000000000433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
401 Nos P, Garrigues V, Bastida G, Maroto N, Ponce M, Ponce J. Outcome of patients with nonstenotic, nonfistulizing Crohn’s disease. Dig Dis Sci. 2004;49:1771-1776. [PMID: 15628701 DOI: 10.1007/s10620-004-9568-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
402 Fidder HH, Olschwang S, Avidan B, Zouali H, Lang A, Bardan E, Picard O, Bar-meir S, Colombel JF, Chowers Y. Association between mutations in theCARD15 (NOD2) gene and Crohn's disease in Israeli Jewish patients. Am J Med Genet 2003;121A:240-4. [DOI: 10.1002/ajmg.a.20209] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
403 Latiano A, Palmieri O, Valvano RM, D'Incà R, Vecchi M, Ferraris A, Sturniolo GC, Spina L, Lombardi G, Dallapiccola B. Contribution of IBD5 locus to clinical features of IBD patients. Am J Gastroenterol. 2006;101:318-325. [PMID: 16454837 DOI: 10.1111/j.1572-0241.2006.00389.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
404 Shanahan F, Bernstein CN. Antibiotics as a First-line Therapy for Crohnʼs Disease: Is There Any Consensus? Inflammatory Bowel Diseases 2004;10:324-6. [DOI: 10.1097/00054725-200405000-00023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
405 Sonnenberg A, Genta RM. Epithelial Dysplasia and Cancer in IBD Strictures. ECCOJC 2015;9:769-75. [DOI: 10.1093/ecco-jcc/jjv108] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
406 Biancheri P, Powell N, Monteleone G, Lord G, MacDonald TT. The challenges of stratifying patients for trials in inflammatory bowel disease. Trends Immunol 2013;34:564-71. [PMID: 24035478 DOI: 10.1016/j.it.2013.08.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
407 Sorrentino D. Preclinical and Undiagnosed Crohnʼs Disease: The Submerged Iceberg. Inflammatory Bowel Diseases 2016;22:476-86. [DOI: 10.1097/mib.0000000000000612] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
408 Miheller P, Kiss LS, Juhasz M, Mandel M, Lakatos PL. Recommendations for identifying Crohn’s disease patients with poor prognosis. Expert Rev Clin Immunol. 2013;9:65-75; quiz 76. [PMID: 23256765 DOI: 10.1586/eci.12.86] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
409 Lakatos PL, Papp M, Rieder F. Serologic antiglycan antibodies in inflammatory bowel disease. Am J Gastroenterol. 2011;106:406-412. [PMID: 21245832 DOI: 10.1038/ajg.2010.505] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
410 Jenkinson PW, Plevris N, Siakavellas S, Lyons M, Arnott ID, Wilson D, Watson AJM, Jones GR, Lees CW. Temporal Trends in Surgical Resection Rates and Biologic Prescribing in Crohn's Disease: A Population-based Cohort Study. J Crohns Colitis 2020;14:1241-7. [PMID: 32840295 DOI: 10.1093/ecco-jcc/jjaa044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
411 Bicette R, Tenjarla G, Kugathasan S, Alazraki A, Haddad L. A 14-year-old girl with recurrent vulvar abscess. J Pediatr Adolesc Gynecol 2014;27:e83-6. [PMID: 24268555 DOI: 10.1016/j.jpag.2013.07.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
412 Alvarez-Lobos M, Arostegui JI, Sans M, Tassies D, Piu J, Reverter JC, Pique JM, Yagüe J, Panés J. Combined type-1 plasminogen activator inhibitor and NOD2/CARD15 genotyping predicts complicated Crohn’s disease behaviour. Aliment Pharmacol Ther. 2007;25:429-440. [PMID: 17269998 DOI: 10.1111/j.1365-2036.2006.03208.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
413 Lee JL, Yoon YS, Yu CS. Treatment Strategy for Perianal Fistulas in Crohn Disease Patients: The Surgeon's Point of View. Ann Coloproctol 2021;37:5-15. [PMID: 33730796 DOI: 10.3393/ac.2021.02.08] [Reference Citation Analysis]
414 Griffiths AM. Enteral feeding in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care 2006;9:314-8. [PMID: 16607134 DOI: 10.1097/01.mco.0000222117.76536.49] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
415 Chen M, Shen B. Endoscopic Therapy in Crohn's Disease: Principle, Preparation, and Technique. Inflamm Bowel Dis. 2015;21:2222-2240. [PMID: 26284298 DOI: 10.1097/mib.0000000000000433] [Cited by in Crossref: 43] [Cited by in F6Publishing: 10] [Article Influence: 8.6] [Reference Citation Analysis]
416 Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H. Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. World J Gastroenterol. 2015;21:21-46. [PMID: 25574078 DOI: 10.3748/wjg.v21.i1.21] [Cited by in CrossRef: 87] [Cited by in F6Publishing: 72] [Article Influence: 14.5] [Reference Citation Analysis]
417 Wehkamp J, Schmid M, Stange EF. Defensins and other antimicrobial peptides in inflammatory bowel disease. Curr Opin Gastroenterol. 2007;23:370-378. [PMID: 17545771 DOI: 10.1097/MOG.0b013e328136c580] [Cited by in Crossref: 116] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
418 Legnani P, Abreu MT. Use of Capsule Endoscopy for Established Crohn's Disease. Gastrointestinal Endoscopy Clinics of North America 2006;16:299-306. [DOI: 10.1016/j.giec.2006.03.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
419 Schmiedlin-Ren P, Reingold LJ, Broxson CS, Rittershaus AC, Brudi JS, Adler J, Owens SR, Zimmermann EM. Anti-TNFα alters the natural history of experimental Crohn's disease in rats when begun early, but not late, in disease. Am J Physiol Gastrointest Liver Physiol 2016;311:G688-98. [PMID: 27562059 DOI: 10.1152/ajpgi.00216.2015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
420 Song XM, Gao X, Li MZ, Chen ZH, Chen SC, Hu PJ, He YL, Zhan WH, Chen MH. Clinical features and risk factors for primary surgery in 205 patients with Crohn's disease: analysis of a South China cohort. Dis Colon Rectum. 2011;54:1147-1154. [PMID: 21825896 DOI: 10.1097/dcr.0b013e318222ddc3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
421 Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, Smith L, Gillett PM, McGrogan P, Weaver LT, Bisset WM, Mahdi G, Arnott ID, Satsangi J, Wilson DC. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135:1114-1122. [PMID: 18725221 DOI: 10.1053/j.gastro.2008.06.081] [Cited by in Crossref: 575] [Cited by in F6Publishing: 478] [Article Influence: 44.2] [Reference Citation Analysis]
422 Mahid SS, Minor KS, Stromberg AJ, Galandiuk S. Active and passive smoking in childhood is related to the development of inflammatory bowel disease. Inflamm Bowel Dis 2007;13:431-8. [PMID: 17206676 DOI: 10.1002/ibd.20070] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 4.1] [Reference Citation Analysis]
423 Lewis A, Mehta S, Hanna LN, Rogalski LA, Jeffery R, Nijhuis A, Kumagai T, Biancheri P, Bundy JG, Bishop CL, Feakins R, Di Sabatino A, Lee JC, Lindsay JO, Silver A. Low Serum Levels of MicroRNA-19 Are Associated with a Stricturing Crohn's Disease Phenotype. Inflamm Bowel Dis. 2015;21:1926-1934. [PMID: 25985247 DOI: 10.1097/mib.0000000000000443] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
424 Meuwis MA, Fillet M, Geurts P, de Seny D, Lutteri L, Chapelle JP, Bours V, Wehenkel L, Belaiche J, Malaise M. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol. 2007;73:1422-1433. [PMID: 17258689 DOI: 10.1016/j.bcp.2006.12.019] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 4.9] [Reference Citation Analysis]
425 Csillag C, Nielsen OH, Borup R, Nielsen FC, Olsen J. Clinical phenotype and gene expression profile in Crohn’s disease. Am J Physiol Gastrointest Liver Physiol. 2007;292:G298-G304. [PMID: 16959948 DOI: 10.1152/ajpgi.00321.2006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
426 Govani SM, Stidham RW, Higgins PD. How early to take arms against a sea of troubles? The case for aggressive early therapy in Crohn's disease to prevent fibrotic intestinal strictures. J Crohns Colitis 2013;7:923-7. [PMID: 23880128 DOI: 10.1016/j.crohns.2013.06.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
427 Wehkamp J, Stange EF. Paneth's disease. J Crohns Colitis. 2010;4:523-531. [PMID: 21122555 DOI: 10.1016/j.crohns.2010.05.010] [Cited by in Crossref: 87] [Cited by in F6Publishing: 71] [Article Influence: 7.9] [Reference Citation Analysis]
428 Chan WPW, Mourad F, Leong RW. Crohn's disease associated strictures. J Gastroenterol Hepatol. 2018;33:998-1008. [PMID: 29427364 DOI: 10.1111/jgh.14119] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 9.3] [Reference Citation Analysis]
429 Solberg IC, Vatn MH, Høie O, Stray N, Sauar J, Jahnsen J, Moum B, Lygren I. Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430-1438. [PMID: 18054751 DOI: 10.1016/j.cgh.2007.09.002] [Cited by in Crossref: 441] [Cited by in F6Publishing: 383] [Article Influence: 33.9] [Reference Citation Analysis]
430 Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15:1295-301. [PMID: 19340881 DOI: 10.1002/ibd.20927] [Cited by in Crossref: 468] [Cited by in F6Publishing: 402] [Article Influence: 39.0] [Reference Citation Analysis]
431 Hünerwadel A, Fagagnini S, Rogler G, Lutz C, Jaeger SU, Mamie C, Weder B, Ruiz PA, Hausmann M. Severity of local inflammation does not impact development of fibrosis in mouse models of intestinal fibrosis. Sci Rep 2018;8:15182. [PMID: 30315190 DOI: 10.1038/s41598-018-33452-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
432 Rieder F, Bettenworth D, Ma C, Parker CE, Williamson LA, Nelson SA, van Assche G, Di Sabatino A, Bouhnik Y, Stidham RW, Dignass A, Rogler G, Taylor SA, Stoker J, Rimola J, Baker ME, Fletcher JG, Panes J, Sandborn WJ, Feagan BG, Jairath V. An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease. Aliment Pharmacol Ther 2018;48:347-57. [PMID: 29920726 DOI: 10.1111/apt.14853] [Cited by in Crossref: 69] [Cited by in F6Publishing: 58] [Article Influence: 23.0] [Reference Citation Analysis]
433 Koslowski MJ, Teltschik Z, Beisner J, Schaeffeler E, Wang G, Kübler I, Gersemann M, Cooney R, Jewell D, Reinisch W. Association of a functional variant in the Wnt co-receptor LRP6 with early onset ileal Crohn’s disease. PLoS Genet. 2012;8:e1002523. [PMID: 22393312 DOI: 10.1371/journal.pgen.1002523] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
434 Heresbach D, Alexandre JL, Bretagne JF, Cruchant E, Dabadie A, Dartois-Hoguin M, Girardot PM, Jouanolle H, Kerneis J, Le Verger JC. Crohn's disease in the over-60 age group: a population based study. Eur J Gastroenterol Hepatol. 2004;16:657-664. [PMID: 15201578 DOI: 10.1097/01.meg.0000108337.41221.08] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 3.8] [Reference Citation Analysis]
435 Cleynen I, González JR, Figueroa C, Franke A, McGovern D, Bortlík M, Crusius BJ, Vecchi M, Artieda M, Szczypiorska M. Genetic factors conferring an increased susceptibility to develop Crohn’s disease also influence disease phenotype: results from the IBDchip European Project. Gut. 2013;62:1556-1565. [PMID: 23263249 DOI: 10.1136/gutjnl-2011-300777] [Cited by in Crossref: 166] [Cited by in F6Publishing: 150] [Article Influence: 18.4] [Reference Citation Analysis]
436 Kayar Y, Baran B, Ormeci AC, Akyuz F, Demir K, Besisik F, Kaymakoglu S. Risk factors associated with progression to intestinal complications of Crohn disease. Chin Med J (Engl) 2019;132:2423-9. [PMID: 31651515 DOI: 10.1097/CM9.0000000000000489] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
437 Kiss LS, Lakatos PL. Prediction of the disease course in inflammatory bowel diseases. Orvosi Hetilap 2010;151:293-301. [DOI: 10.1556/oh.2010.28813] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
438 Golovics PA, Mandel MD, Lovasz BD, Lakatos PL. Inflammatory bowel disease course in Crohn’s disease: is the natural history changing? World J Gastroenterol. 2014;20:3198-3207. [PMID: 24696605 DOI: 10.3748/wjg.v20.i12.3198] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
439 Yang SB, Du SW, Wang JH. Correlation between age of onset and gastrointestinal stenosis in hospitalized patients with Crohn's disease. World J Clin Cases 2020;8:2769-77. [PMID: 32742987 DOI: 10.12998/wjcc.v8.i13.2769] [Reference Citation Analysis]
440 Shyn PB. 18F-FDG positron emission tomography: potential utility in the assessment of Crohn’s disease. Abdom Imaging. 2012;37:377-386. [PMID: 21833729 DOI: 10.1007/s00261-011-9793-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
441 Botti F, Caprioli F, Pettinari D, Carrara A, Magarotto A, Contessini Avesani E. Surgery and diagnostic imaging in abdominal Crohn's disease. J Ultrasound 2015;18:3-17. [PMID: 25767635 DOI: 10.1007/s40477-013-0037-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
442 Savoye G, Salleron J, Gower-rousseau C, Dupas J, Vernier-massouille G, Fumery M, Merle V, Lerebours E, Cortot A, Turck D, Salomez J, Lemann M, Colombel J, Duhamel A. Clinical predictors at diagnosis of disabling pediatric Crohnʼs disease: . Inflammatory Bowel Diseases 2012;18:2072-8. [DOI: 10.1002/ibd.22898] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
443 Ahmed Ali U, Martin ST, Rao AD, Kiran RP. Impact of preoperative immunosuppressive agents on postoperative outcomes in Crohn’s disease. Dis Colon Rectum. 2014;57:663-674. [PMID: 24819109 DOI: 10.1097/dcr.0000000000000099] [Cited by in Crossref: 48] [Cited by in F6Publishing: 14] [Article Influence: 6.9] [Reference Citation Analysis]
444 Bossuyt P, Debeuckelaere C, Ferrante M, de Buck van Overstraeten A, Vanbeckevoort D, Billiet T, Wolthuis A, Cleynen I, Van Assche G, D’hoore A, Vermeire S. Risk Stratification for Surgery in Stricturing Ileal Crohn’s Disease: The BACARDI Risk Model. Journal of Crohn's and Colitis 2018;12:32-8. [DOI: 10.1093/ecco-jcc/jjx110] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
445 Ooi CJ, Makharia GK, Hilmi I, Gibson PR, Fock KM, Ahuja V, Ling KL, Lim WC, Thia KT, Wei SC, Leung WK, Koh PK, Gearry RB, Goh KL, Ouyang Q, Sollano J, Manatsathit S, de Silva HJ, Rerknimitr R, Pisespongsa P, Abu Hassan MR, Sung J, Hibi T, Boey CC, Moran N, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease. Asia-Pacific consensus statements on Crohn's disease. Part 2: Management. J Gastroenterol Hepatol. 2016;31:56-68. [PMID: 25819311 DOI: 10.1111/jgh.12958] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
446 Sinha R, Murphy P, Sanders S, Ramachandran I, Hawker P, Rawat S, Roberts S. Diagnostic accuracy of high-resolution MR enterography in Crohn's disease: Comparison with surgical and pathological specimen. Clinical Radiology 2013;68:917-27. [DOI: 10.1016/j.crad.2013.02.012] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 4.9] [Reference Citation Analysis]
447 Li Y, Zhu W, Zuo L, Zhang W, Gong J, Gu L, Cao L, Li N, Li J. Frequency and risk factors of postoperative recurrence of Crohn’s disease after intestinal resection in the Chinese population. J Gastrointest Surg. 2012;16:1539-1547. [PMID: 22555673 DOI: 10.1007/s11605-012-1902-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
448 Perminow G, Beisner J, Koslowski M, Lyckander LG, Stange E, Vatn MH, Wehkamp J. Defective paneth cell-mediated host defense in pediatric ileal Crohn’s disease. Am J Gastroenterol. 2010;105:452-459. [PMID: 19904243 DOI: 10.1038/ajg.2009.643] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 4.0] [Reference Citation Analysis]
449 Al-Hawary M, Zimmermann EM. A new look at Crohn’s disease: novel imaging techniques. Curr Opin Gastroenterol. 2012;28:334-340. [PMID: 22678451 DOI: 10.1097/mog.0b013e3283540705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.1] [Reference Citation Analysis]
450 Iacucci M, de Silva S, Ghosh S. Mesalazine in inflammatory bowel disease: a trendy topic once again? Can J Gastroenterol 2010;24:127-33. [PMID: 20151072 DOI: 10.1155/2010/586092] [Cited by in Crossref: 52] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
451 Coelho J, Soyer P, Pautrat K, Boudiaf M, Vahedi K, Reignier S, Valleur P, Marteau P. [Management of ileal stenosis in patients with Crohn’s disease]. Gastroenterol Clin Biol. 2009;33:F75-F81. [PMID: 19733458 DOI: 10.1016/j.gcb.2009.07.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
452 van Haaften WT, Mortensen JH, Karsdal MA, Bay-Jensen AC, Dijkstra G, Olinga P. Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease. Aliment Pharmacol Ther 2017;46:26-39. [PMID: 28481042 DOI: 10.1111/apt.14092] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
453 Picco MF, Zubiaurre I, Adluni M, Cangemi JR, Shelton D. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn’s disease. Am J Gastroenterol. 2009;104:2754-2759. [PMID: 19584832 DOI: 10.1038/ajg.2009.387] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
454 Picco MF, Bayless TM. Tobacco consumption and disease duration are associated with fistulizing and stricturing behaviors in the first 8 years of Crohn's disease. Am J Gastroenterol 2003;98:363-8. [PMID: 12591056 DOI: 10.1111/j.1572-0241.2003.07240.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 79] [Article Influence: 4.3] [Reference Citation Analysis]
455 Maggiori L, Panis Y. Laparoscopy in Crohn’s disease. Best Pract Res Clin Gastroenterol. 2014;28:183-194. [PMID: 24485265 DOI: 10.1016/j.bpg.2013.11.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
456 Bossuyt P, Debeuckelaere C, Ferrante M, Vanbeckevoort D, Billiet T, Wolthuis A, van Assche G, D’hoore A, Vermeire S. The operative risk and natural history after the diagnosis of ileal penetrating Crohn’s disease: . European Journal of Gastroenterology & Hepatology 2018;30:539-45. [DOI: 10.1097/meg.0000000000001091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
457 Lian L, Huang Q, Zhang L, Qin H, He X, He X, Ke J, Xie M, Lan P. Anti-fibrogenic Potential of Mesenchymal Stromal Cells in Treating Fibrosis in Crohn’s Disease. Dig Dis Sci 2018;63:1821-34. [DOI: 10.1007/s10620-018-5082-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
458 Fidder HH, Avidan B, Lahav M, Bar-Meir S, Chowers Y. Clinical and demographic characterization of Jewish Crohn’s disease patients in Israel. J Clin Gastroenterol. 2003;36:8-12. [PMID: 12488699 DOI: 10.1097/00004836-200301000-00005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.2] [Reference Citation Analysis]
459 Pelletier AL, Stefanescu C, Vincent C, Etienney I, Mentré F, Soulé JC. Is the length of postoperative recurrence on the neo ileum terminal ileum predictable in Crohn's disease? J Crohns Colitis 2011;5:24-7. [PMID: 21272800 DOI: 10.1016/j.crohns.2010.08.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
460 Fiorino G, Bonifacio C, Peyrin-Biroulet L, Danese S. Preventing Collateral Damage in Crohn's Disease: The Lémann Index. J Crohns Colitis 2016;10:495-500. [PMID: 26744441 DOI: 10.1093/ecco-jcc/jjv240] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
461 Colombel JF, Rutgeerts PJ, Sandborn WJ, Yang M, Camez A, Pollack PF, Thakkar RB, Robinson AM, Chen N, Mulani PM, Chao J. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014; 12: 414-22. e5. [PMID: 23856361 DOI: 10.1016/j.cgh.2013.06.019] [Cited by in Crossref: 149] [Cited by in F6Publishing: 126] [Article Influence: 18.6] [Reference Citation Analysis]
462 Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP. Differential Effects of NOD2 Variants on Crohn's Disease Risk and Phenotype in Diverse Populations: A Metaanalysis. Am J Gastroenterology 2004;99:2393-404. [DOI: 10.1111/j.1572-0241.2004.40304.x] [Cited by in Crossref: 317] [Cited by in F6Publishing: 295] [Article Influence: 18.6] [Reference Citation Analysis]
463 Torkzad MR, Ullberg U, Nyström N, Blomqvist L, Hellström P, Fagerberg UL. Manifestations of small bowel disease in pediatric Crohn's disease on magnetic resonance enterography. Inflamm Bowel Dis 2012;18:520-8. [PMID: 21538711 DOI: 10.1002/ibd.21725] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
464 Vidigal FM, de Souza GS, Chebli LA, da Rocha Ribeiro TC, Furtado MC, Castro AC, Pinto AL, do Valle Pinheiro B, de Lima Pace FH, Machado de Oliveira J, de Oliveira Zanini KA, Gaburri PD, Zanini A, Ribeiro LC, Chebli JM. Azathioprine is more effective than mesalazine at preventing recurrent bowel obstruction in patients with ileocecal Crohn's disease. Med Sci Monit 2014;20:2165-70. [PMID: 25370731 DOI: 10.12659/MSM.890975] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
465 Mckenna NP, Bews KA, Habermann EB, Dozois EJ, Lightner AL, Mathis KL. What Factors Are Associated With the Eventual Need for an Ileostomy After Total Abdominal Colectomy and Ileosigmoid or Ileorectal Anastomosis for Crohn’s Colitis in the Biologic Era? Diseases of the Colon & Rectum 2020;63:504-13. [DOI: 10.1097/dcr.0000000000001556] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
466 Correa I, Veny M, Esteller M, Piqué JM, Yagüe J, Panés J, Salas A. Defective IL-10 production in severe phenotypes of Crohn’s disease. J Leukoc Biol. 2009;85:896-903. [PMID: 19237638 DOI: 10.1189/jlb.1108698] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
467 Pernat Drobež C, Repnik K, Gorenjak M, Ferkolj I, Weersma RK, Potočnik U. DNA polymorphisms predict time to progression from uncomplicated to complicated Crohn's disease. Eur J Gastroenterol Hepatol 2018;30:447-55. [PMID: 29293112 DOI: 10.1097/MEG.0000000000001055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
468 Gearry RB, Roberts RL, Burt MJ, Frampton CM, Chapman BA, Collett JA, Shirley P, Allington MD, Kennedy MA, Barclay ML. Effect of inflammatory bowel disease classification changes on NOD2 genotype-phenotype associations in a population-based cohort. Inflamm Bowel Dis. 2007;13:1220-1227. [PMID: 17538984 DOI: 10.1002/ibd.20190] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
469 Moran GW, Dubeau MF, Kaplan GG, Panaccione R, Ghosh S. Novel concepts in inflammatory bowel disease. British Medical Bulletin 2014;109:55-72. [DOI: 10.1093/bmb/ldt039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
470 Michetti P, Juillerat P, Mottet C, Pittet V, Gonvers J, Vader J, Froehlich F, Felley C. Mild-to-Moderate Active Luminal Crohn’s Disease. Digestion 2008;76:92-8. [DOI: 10.1159/000111022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
471 Moffatt D, Bernstein CN. State-of-the-Art Medical Therapy of the Adult Patient with IBD: The Immunomodulators. In: Cohen RD, editor. Inflammatory Bowel Disease. Totowa: Humana Press; 2011. pp. 93-110. [DOI: 10.1007/978-1-60327-433-3_7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
472 Mahid SS, Minor KS, Stevens PL, Galandiuk S. The role of smoking in Crohn's disease as defined by clinical variables. Dig Dis Sci 2007;52:2897-903. [PMID: 17401688 DOI: 10.1007/s10620-006-9624-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 3.4] [Reference Citation Analysis]
473 Soh H, Im JP, Han K, Park S, Hong SW, Moon JM, Kang EA, Chun J, Lee HJ, Kim JS. Crohn's disease and ulcerative colitis are associated with different lipid profile disorders: a nationwide population-based study. Aliment Pharmacol Ther. 2020;51:446-456. [PMID: 31691306 DOI: 10.1111/apt.15562] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
474 Chhaya V, Pollok RCG, Cecil E, Subramanian V, Curcin V, Majeed A, Saxena S. Impact of early thiopurines on surgery in 2770 children and young people diagnosed with inflammatory bowel disease: a national population-based study. Aliment Pharmacol Ther 2015;42:990-9. [DOI: 10.1111/apt.13361] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
475 Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, Merle V, Salomez JL, Branche J, Marti R, Lerebours E, Cortot A, Gower-Rousseau C, Colombel JF. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology. 2008;135:1106-1113. [PMID: 18692056 DOI: 10.1053/j.gastro.2008.06.079] [Cited by in Crossref: 390] [Cited by in F6Publishing: 327] [Article Influence: 30.0] [Reference Citation Analysis]
476 Maccioni F, Staltari I, Pino AR, Tiberti A. Value of T2-weighted magnetic resonance imaging in the assessment of wall inflammation and fibrosis in Crohn’s disease. Abdom Imaging. 2012;37:944-957. [PMID: 22639331 DOI: 10.1007/s00261-012-9853-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
477 Palmieri O, Latiano A, Valvano R, D’Incà R, Vecchi M, Sturniolo GC, Saibeni S, Peyvandi F, Bossa F, Zagaria C. Variants of OCTN1-2 cation transporter genes are associated with both Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther. 2006;23:497-506. [PMID: 16441470 DOI: 10.1111/j.1365-2036.2006.02780.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
478 Gordon IO, Agrawal N, Willis E, Goldblum JR, Lopez R, Allende D, Liu X, Patil DY, Yerian L, El-Khider F, Fiocchi C, Rieder F. Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation. Aliment Pharmacol Ther 2018;47:922-39. [PMID: 29411405 DOI: 10.1111/apt.14526] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 14.3] [Reference Citation Analysis]
479 Reinhard C, Rioux JD. Role of the IBD5 susceptibility locus in the inflammatory bowel diseases. Inflamm Bowel Dis. 2006;12:227-238. [PMID: 16534425 DOI: 10.1097/01.mib.0000202413.16360.a1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
480 Johnson LA, Govani SM, Joyce JC, Waljee AK, Gillespie BW, Higgins PD. Spironolactone and colitis: increased mortality in rodents and in humans. Inflamm Bowel Dis 2012;18:1315-24. [PMID: 22081497 DOI: 10.1002/ibd.21929] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
481 Park SJ, Kim WH, Cheon JH. Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives. World J Gastroenterol 2014;20:11525-37. [PMID: 25206259 DOI: 10.3748/wjg.v20.i33.11525] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 60] [Article Influence: 10.8] [Reference Citation Analysis]
482 Fumery M, Yzet C, Chatelain D, Yzet T, Brazier F, LeMouel JP, Laharie D, Sabbagh C. Colonic strictures in inflammatory bowel disease: epidemiology, complications, and management. J Crohns Colitis 2021:jjab068. [PMID: 33844013 DOI: 10.1093/ecco-jcc/jjab068] [Reference Citation Analysis]
483 Greener T, Klang E, Yablecovitch D, Lahat A, Neuman S, Levhar N, Avidan B, Yanai H, Dotan I, Chowers Y, Weiss B, Saibil F, Amitai MM, Ben-Horin S, Kopylov U, Eliakim R; Israeli IBD Research Nucleus (IIRN). The Impact of Magnetic Resonance Enterography and Capsule Endoscopy on the Re-classification of Disease in Patients with Known Crohn's Disease: A Prospective Israeli IBD Research Nucleus (IIRN) Study. J Crohns Colitis. 2016;10:525-531. [PMID: 26748404 DOI: 10.1093/ecco-jcc/jjw006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
484 Bergeron F, Bouin M, D'Aoust L, Lemoyne M, Presse N. Food avoidance in patients with inflammatory bowel disease: What, when and who? Clin Nutr 2018;37:884-9. [PMID: 28359542 DOI: 10.1016/j.clnu.2017.03.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
485 Shivaji UN, Evans M, Critchlow T, Gui X, Smith SCL, Pinkney T, Iacucci M, Cooney R, Ghosh S, Skordilis K. Chronic inflammation and other changes are significant components of clinically fibrotic strictures in Crohn's disease: a histological study of resected strictures clinically characterized as noninflamed. Eur J Gastroenterol Hepatol 2020;32:1432-9. [PMID: 32639416 DOI: 10.1097/MEG.0000000000001796] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
486 Stenke E, Bourke B, Knaus U. Crohn's Strictures-Moving Away from the Knife.Front Pediatr. 2017;5:141. [PMID: 28670577 DOI: 10.3389/fped.2017.00141] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
487 Lakatos PL, Kiss LS. Is the disease course predictable in inflammatory bowel diseases? World J Gastroenterol 2010;16:2591-9. [PMID: 20518079 DOI: 10.3748/wjg.v16.i21.2591] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
488 Michetti P, Juillerat P, Mottet C, Gonvers J, Burnand B, Vader J, Froehlich F, Felley C. Therapy of Mild to Moderate Luminal Crohn’s Disease. Digestion 2005;71:13-8. [DOI: 10.1159/000083866] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
489 Modha K, Navaneethan U. Advanced therapeutic endoscopist and inflammatory bowel disease: dawn of a new role. World J Gastroenterol. 2014;20:3485-3494. [PMID: 24707131 DOI: 10.3748/wjg.v20.i13.3485] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
490 Sampietro GM, Cristaldi M, Maconi G, Parente F, Sartani A, Ardizzone S, Danelli P, Porro GB, Taschieri AM. A prospective, longitudinal study of nonconventional strictureplasty in Crohn’s disease1 1No competing interests declared. Journal of the American College of Surgeons 2004;199:8-20. [DOI: 10.1016/j.jamcollsurg.2004.01.039] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
491 Lee HW, Park SJ, Jeon SR, Ye BD, Park JJ, Cheon JH, Kim TI, Kim WH; Korean Association for the Study of the Intestinal Diseases (KASID). Long-Term Outcomes of Endoscopic Balloon Dilation for Benign Strictures in Patients with Inflammatory Bowel Disease. Gut Liver 2018;12:530-6. [PMID: 29730904 DOI: 10.5009/gnl17396] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
492 Magro F, Rodrigues-Pinto E, Coelho R, Andrade P, Santos-Antunes J, Lopes S, Camila-Dias C, Macedo G. Is it possible to change phenotype progression in Crohn's disease in the era of immunomodulators? Predictive factors of phenotype progression. Am J Gastroenterol. 2014;109:1026-1036. [PMID: 24796767 DOI: 10.1038/ajg.2014.97] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 8.7] [Reference Citation Analysis]
493 Mahavadi S, Flynn RS, Grider JR, Qiao LY, Murthy KS, Hazelgrove KB, Kuemmerle JF. Amelioration of excess collagen IαI, fibrosis, and smooth muscle growth in TNBS-induced colitis in IGF-I(+/-) mice. Inflamm Bowel Dis 2011;17:711-9. [PMID: 20722057 DOI: 10.1002/ibd.21437] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
494 Pinto S, Loddo E, Paba S, Favale A, Chicco F, Onali S, Usai P, Fantini MC. Crohn's disease and ulcerative colitis patient-reported outcomes signs and symptoms for the remote management of inflammatory bowel disease during the COVID-19 pandemic. J Patient Rep Outcomes 2021;5:48. [PMID: 34165646 DOI: 10.1186/s41687-021-00323-z] [Reference Citation Analysis]
495 Sun XW, Wei J, Yang Z, Jin XX, Wan HJ, Yuan BS, Yang MF, Liu J, Wang FY. Clinical Features and Prognosis of Crohn's Disease with Upper Gastrointestinal Tract Phenotype in Chinese Patients. Dig Dis Sci 2019;64:3291-9. [PMID: 31079261 DOI: 10.1007/s10620-019-05651-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
496 Helper DJ. Medical management of Crohn's disease: A guide for radiologists. European Journal of Radiology 2009;69:371-4. [DOI: 10.1016/j.ejrad.2008.11.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
497 Kühl AA, Erben U, Kredel LI, Siegmund B. Diversity of Intestinal Macrophages in Inflammatory Bowel Diseases. Front Immunol 2015;6:613. [PMID: 26697009 DOI: 10.3389/fimmu.2015.00613] [Cited by in Crossref: 87] [Cited by in F6Publishing: 82] [Article Influence: 14.5] [Reference Citation Analysis]
498 Reenaers C, Belaiche J, Louis E. Impact of medical therapies on inflammatory bowel disease complication rate. World J Gastroenterol. 2012;18:3823-3827. [PMID: 22876033 DOI: 10.3748/wjg.v18.i29.3823] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
499 Grassl GA, Valdez Y, Bergstrom KS, Vallance BA, Finlay BB. Chronic enteric salmonella infection in mice leads to severe and persistent intestinal fibrosis. Gastroenterology. 2008;134:768-780. [PMID: 18325390 DOI: 10.1053/j.gastro.2007.12.043] [Cited by in Crossref: 91] [Cited by in F6Publishing: 88] [Article Influence: 7.0] [Reference Citation Analysis]
500 Oostenbrug LE, van Dullemen HM, te Meerman GJ, Jansen PL, Kleibeuker JH. Clinical outcome of Crohn’s disease according to the Vienna classification: disease location is a useful predictor of disease course. Eur J Gastroenterol Hepatol. 2006;18:255-261. [PMID: 16462538 DOI: 10.1097/00042737-200603000-00005] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
501 Cunningham MF, Docherty NG, Coffey JC, Burke JP, O’Connell PR. Postsurgical recurrence of ileal Crohn’s disease: an update on risk factors and intervention points to a central role for impaired host-microflora homeostasis. World J Surg. 2010;34:1615-1626. [PMID: 20195604 DOI: 10.1007/s00268-010-0504-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
502 Das R, Singh R, Din S, Lund J, Krishnamoorthy R, Hearing S, Norton B, Williams J, Fraser C, Goddard A, Cole A. Therapeutic resolution of focal, predominantly anastomotic Crohn’s disease strictures using removable stents: outcomes from a single-center case series in the United Kingdom. Gastrointestinal Endoscopy 2020;92:344-52. [DOI: 10.1016/j.gie.2020.01.053] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
503 Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-1657. [PMID: 17499606 DOI: 10.1016/s0140-6736(07)60751-x] [Cited by in Crossref: 1121] [Cited by in F6Publishing: 456] [Article Influence: 80.1] [Reference Citation Analysis]
504 Cullen G, Keegan D, Mulcahy HE, O'donoghue DP. A 5-Year Prospective Observational Study of the Outcomes of International Treatment Guidelines for Crohn's Disease. Clinical Gastroenterology and Hepatology 2009;7:323-8. [DOI: 10.1016/j.cgh.2008.10.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
505 Ma C, Jairath V, Click B, Hirota SA, Lu C, Parker CE, Rieder F; Stenosis Therapy and Anti-Fibrotic Research (STAR) Consortium. Targeting anti-fibrotic pathways in Crohn's disease - The final frontier? Best Pract Res Clin Gastroenterol 2019;38-39:101603. [PMID: 31327400 DOI: 10.1016/j.bpg.2019.02.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
506 Nguyen VQ, Jiang D, Hoffman SN, Guntaka S, Mays JL, Wang A, Gomes J, Sorrentino D. Impact of Diagnostic Delay and Associated Factors on Clinical Outcomes in a U.S. Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis. 2017;23:1825-1831. [PMID: 28885229 DOI: 10.1097/mib.0000000000001257] [Cited by in Crossref: 38] [Cited by in F6Publishing: 15] [Article Influence: 12.7] [Reference Citation Analysis]
507 Kalaria R, Desai D, Abraham P, Joshi A, Gupta T, Shah S. Temporal Change in Phenotypic Behaviour in Patients with Crohn's Disease: Do Indian Patients Behave Differently from Western and Other Asian Patients? J Crohns Colitis. 2016;10:255-261. [PMID: 26519461 DOI: 10.1093/ecco-jcc/jjv202] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
508 Caprilli R, Guagnozzi D. CARD15 and Toll-like receptors: the link with Crohn’s disease. Digestive and Liver Disease 2003;35:753-7. [DOI: 10.1016/s1590-8658(03)00461-4] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
509 Reenaers C, Louis E, Belaiche J. Current directions of biologic therapies in inflammatory bowel disease. Therap Adv Gastroenterol. 2010;3:99-106. [PMID: 21180594 DOI: 10.1177/1756283x09356872] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
510 Ahmad T, Marshall S, Jewell D. Genotype-based phenotyping heralds a new taxonomy for inflammatory bowel disease: . Current Opinion in Gastroenterology 2003;19:327-35. [DOI: 10.1097/00001574-200307000-00002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
511 Brand S, Staudinger T, Schnitzler F, Pfennig S, Hofbauer K, Dambacher J, Seiderer J, Tillack C, Konrad A, Crispin A, Göke B, Lohse P, Ochsenkühn T. The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis 2005;11:645-52. [PMID: 15973118 DOI: 10.1097/01.mib.0000168372.94907.d2] [Cited by in Crossref: 117] [Cited by in F6Publishing: 43] [Article Influence: 7.3] [Reference Citation Analysis]
512 Patel SH, Rachchh MA, Jadav PD. Evaluation of anti-inflammatory effect of anti-platelet agent-clopidogrel in experimentally induced inflammatory bowel disease. Indian J Pharmacol. 2012;44:744-748. [PMID: 23248405 DOI: 10.4103/0253-7613] [Reference Citation Analysis]
513 Chen B, Zeng Z, Hou J, Chen M, Gao X, Hu P. Association of interleukin-17F 7488 single nucleotide polymorphism and inflammatory bowel disease in the Chinese population. Scand J Gastroenterol. 2009;44:720-726. [PMID: 19263269 DOI: 10.1080/00365520902795430] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
514 Gasparetto M, Angriman I, Guariso G. The multidisciplinary health care team in the management of stenosis in Crohn's disease. J Multidiscip Healthc 2015;8:167-79. [PMID: 25878504 DOI: 10.2147/JMDH.S38729] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
515 Langholz E. Current trends in inflammatory bowel disease: the natural history. Therap Adv Gastroenterol. 2010;3:77-86. [PMID: 21180592 DOI: 10.1177/1756283x10361304] [Cited by in Crossref: 52] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
516 Shaoul R, Karban A, Reif S, Weiss B, Shamir R, Tamir A, Davidovich O, Halevi J, Silver EL, Levine A. Disease behavior in children with Crohn’s disease: the effect of disease duration, ethnicity, genotype, and phenotype. Dig Dis Sci. 2009;54:142-150. [PMID: 18594982 DOI: 10.1007/s10620-008-0326-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
517 Lakatos PL, Czegledi Z, Szamosi T, Banai J, David G, Zsigmond F, Pandur T, Erdelyi Z, Gemela O, Papp J, Lakatos L. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. World J Gastroenterol. 2009;15:3504-3510. [PMID: 19630105 DOI: 10.3748/wjg.15.3504] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 79] [Article Influence: 6.3] [Reference Citation Analysis]
518 Solberg IC, Cvancarova M, Vatn MH, Moum B; IBSEN Study Group. Risk matrix for prediction of advanced disease in a population-based study of patients with Crohn's Disease (the IBSEN Study). Inflamm Bowel Dis. 2014;20:60-68. [PMID: 24280875 DOI: 10.1097/01.mib.0000436956.78220.67] [Cited by in Crossref: 36] [Cited by in F6Publishing: 14] [Article Influence: 5.1] [Reference Citation Analysis]
519 Louis E. Epidemiology of the transition from early to late Crohn’s disease. Dig Dis. 2012;30:376-379. [PMID: 22796799 DOI: 10.1159/000338129] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
520 Bafford AC, Latushko A, Hansraj N, Jambaulikar G, Ghazi LJ. The Use of Temporary Fecal Diversion in Colonic and Perianal Crohn's Disease Does Not Improve Outcomes.Dig Dis Sci. 2017;62:2079-2086. [PMID: 28550490 DOI: 10.1007/s10620-017-4618-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
521 Lan N, Shen B. Endoscopic Stricturotomy with Needle Knife in the Treatment of Strictures from Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23:502-513. [PMID: 28296818 DOI: 10.1097/mib.0000000000001044] [Cited by in Crossref: 52] [Cited by in F6Publishing: 7] [Article Influence: 17.3] [Reference Citation Analysis]
522 Vermeire S, Van Assche G, Rutgeerts P. Classification of inflammatory bowel disease: the old and the new. Curr Opin Gastroenterol. 2012;28:321-326. [PMID: 22647554 DOI: 10.1097/mog.0b013e328354be1e] [Cited by in Crossref: 40] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
523 Lacher M, Helmbrecht J, Schroepf S, Koletzko S, Ballauff A, Classen M, Uhlig H, Hubertus J, Hartl D, Lohse P. NOD2 mutations predict the risk for surgery in pediatric-onset Crohn’s disease. J Pediatr Surg. 2010;45:1591-1597. [PMID: 20713205 DOI: 10.1016/j.jpedsurg.2009.10.046] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
524 Alegbeleye BJ. Crohn's disease in a developing African mission hospital: a case report. J Med Case Rep. 2019;13:80. [PMID: 30846003 DOI: 10.1186/s13256-019-1971-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
525 Koslowski MJ, Kübler I, Chamaillard M, Schaeffeler E, Reinisch W, Wang G, Beisner J, Teml A, Peyrin-Biroulet L, Winter S. Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn’s disease. PLoS One. 2009;4:e4496. [PMID: 19221600 DOI: 10.1371/journal.pone.00 04496] [Reference Citation Analysis]
526 Nguyen GC, Torres EA, Regueiro M, Bromfield G, Bitton A, Stempak J, Dassopoulos T, Schumm P, Gregory FJ, Griffiths AM. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol. 2006;101:1012-1023. [PMID: 16696785 DOI: 10.1111/j.1572-0241.2006.00504.x] [Cited by in Crossref: 172] [Cited by in F6Publishing: 152] [Article Influence: 11.5] [Reference Citation Analysis]
527 Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, Ochsenkühn T, Orchard T, Rogler G, Louis E, Kupcinskas L, Mantzaris G, Travis S, Stange E; for the European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. Journal of Crohn's and Colitis 2010;4:7-27. [DOI: 10.1016/j.crohns.2009.12.003] [Cited by in Crossref: 762] [Cited by in F6Publishing: 649] [Article Influence: 69.3] [Reference Citation Analysis]
528 Zou ZY, Shen B, Fan JG. Systematic Review with Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;25:1764-1772. [PMID: 30918952 DOI: 10.1093/ibd/izz043] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 19.0] [Reference Citation Analysis]
529 Ng SC, Kamm MA. Management of Postoperative Crohn's Disease. Am J Gastroenterology 2008;103:1029-35. [DOI: 10.1111/j.1572-0241.2008.01795.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
530 Mak JWY, Ng SC. Epidemiology of fibrostenosing inflammatory bowel disease. J Dig Dis 2020;21:332-5. [PMID: 32105396 DOI: 10.1111/1751-2980.12853] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
531 Kaushal P, Somwaru AS, Charabaty A, Levy AD. MR Enterography of Inflammatory Bowel Disease with Endoscopic Correlation. RadioGraphics 2017;37:116-31. [DOI: 10.1148/rg.2017160064] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
532 Serra I, Oller B, Mañosa M, Naves JE, Zabana Y, Cabré E, Domènech E. Systemic amyloidosis in inflammatory bowel disease: retrospective study on its prevalence, clinical presentation, and outcome. J Crohns Colitis. 2010;4:269-274. [PMID: 21122515 DOI: 10.1016/j.crohns.2009.11.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
533 Riis L, Munkholm P, Binder V, Skovgaard LT, Langholz E. Intra- and interobserver variation in the use of the Vienna classification of Crohn's disease. Inflamm Bowel Dis. 2005;11:657-661. [PMID: 15973120 DOI: 10.1097/01.MIB.0000165115.18310.e7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
534 Goran L, Negreanu AM, Stemate A, Negreanu L. Capsule endoscopy: Current status and role in Crohn's disease. World J Gastrointest Endosc 2018;10:184-92. [PMID: 30283601 DOI: 10.4253/wjge.v10.i9.184] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
535 Siegmund B, Feakins RM, Barmias G, Ludvig JC, Teixeira FV, Rogler G, Scharl M. Results of the Fifth Scientific Workshop of the ECCO (II): Pathophysiology of Perianal Fistulizing Disease. J Crohns Colitis. 2016;10:377-386. [PMID: 26681764 DOI: 10.1093/ecco-jcc/jjv228] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
536 Kanaan Z, Ahmad S, Roberts H, Thé T, Girdler S, Pan J, Rai SN, Weller EB Jr, Galandiuk S. Crohn's disease in Caucasians and African Americans, as defined by clinical predictors and single nucleotide polymorphisms. J Natl Med Assoc 2012;104:420-7. [PMID: 23342815 DOI: 10.1016/s0027-9684(15)30195-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
537 Baillie CT, Smith JA. Surgical strategies in paediatric inflammatory bowel disease. World J Gastroenterol 2015;21:6101-16. [PMID: 26034347 DOI: 10.3748/wjg.v21.i20.6101] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
538 Tzivras M, Koussoulas V, Giamarellos-Bourboulis EJ, Tzivras D, Tsaganos T, Koutoukas P, Giamarellou H, Archimandritis A. Role of soluble triggering receptor expressed on myeloid cells in inflammatory bowel disease. World J Gastroenterol 2006;12:3416-9. [PMID: 16733861 DOI: 10.3748/wjg.v12.i21.3416] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 52] [Article Influence: 3.0] [Reference Citation Analysis]
539 Siegmund B. Medical Therapy of Fibrostenotic Crohn's Disease. Viszeralmedizin 2015;31:259-64. [PMID: 26557834 DOI: 10.1159/000435868] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
540 Thia KT, Loftus EV, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008;103:3167-3182. [PMID: 19086963 DOI: 10.1111/j.1572-0241.2008.02158.x] [Cited by in Crossref: 337] [Cited by in F6Publishing: 324] [Article Influence: 28.1] [Reference Citation Analysis]
541 Dubinsky MC, Fleshner PP. Treatment of Crohn’s disease of inflammatory, stenotic, and fistulizing phenotypes. Curr Treat Options Gastro 2003;6:183-200. [DOI: 10.1007/s11938-003-0001-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
542 Ungaro RC, Aggarwal S, Topaloglu O, Lee WJ, Clark R, Colombel JF. Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease. Aliment Pharmacol Ther 2020;51:831-42. [PMID: 32202328 DOI: 10.1111/apt.15685] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 14.0] [Reference Citation Analysis]
543 Lee H, Cleynen I. Molecular Profiling of IBD Subtypes and Therapy Responses. In: Hedin C, Rioux JD, D'amato M, editors. Molecular Genetics of Inflammatory Bowel Disease. Cham: Springer International Publishing; 2019. pp. 157-82. [DOI: 10.1007/978-3-030-28703-0_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
544 Fedorak RN. Is it time to re-classify Crohn's disease? Best Pract Res Clin Gastroenterol 2004;18 Suppl:99-106. [PMID: 15588801 DOI: 10.1016/j.bpg.2004.06.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
545 Rieder F, Lopez R, Franke A, Wolf A, Schleder S, Dirmeier A, Schirbel A, Rosenstiel P, Dotan N, Schreiber S. Characterization of changes in serum anti-glycan antibodies in Crohn’s disease--a longitudinal analysis. PLoS One. 2011;6:e18172. [PMID: 21573154 DOI: 10.1371/journal.pone.0018172] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
546 Arnott ID, Satsangi J. Crohn's disease or Crohn's diseases? Gut 2003;52:460-1. [PMID: 12631650 DOI: 10.1136/gut.52.4.460] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
547 Van Assche G, Vermeire S, Rutgeerts P. The potential for disease modification in Crohn's disease. Nat Rev Gastroenterol Hepatol. 2010;7:79-85. [PMID: 20134489 DOI: 10.1038/nrgastro.2009.220] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 5.3] [Reference Citation Analysis]
548 Li Y, Stocchi L, Shen B, Liu X, Remzi FH. Salvage surgery after failure of endoscopic balloon dilatation versus surgery first for ileocolonic anastomotic stricture due to recurrent Crohn's disease. Br J Surg 2015;102:1418-25; discussion 1425. [PMID: 26313750 DOI: 10.1002/bjs.9906] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
549 Núñez C, Barreiro M, Domínguez-Muñoz JE, Lorenzo A, Zapata C, Peña AS. CARD15 mutations in patients with Crohn's disease in a homogeneous Spanish population. Am J Gastroenterol. 2004;99:450-456. [PMID: 15056084 DOI: 10.1111/j.1572-0241.2004.04066.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
550 Yilmaz B, Spalinger MR, Biedermann L, Franc Y, Fournier N, Rossel JB, Juillerat P, Rogler G, Macpherson AJ, Scharl M. The presence of genetic risk variants within PTPN2 and PTPN22 is associated with intestinal microbiota alterations in Swiss IBD cohort patients. PLoS One 2018;13:e0199664. [PMID: 29965986 DOI: 10.1371/journal.pone.0199664] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
551 Gardenbroek TJ, Tanis PJ, Buskens CJ, Bemelman WA. Surgery for Crohn’s disease: new developments. Dig Surg. 2012;29:275-280. [PMID: 22922840 DOI: 10.1159/000341567] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
552 Gilletta C, Lewin M, Bourrier A, Nion-Larmurier I, Rajca S, Beaugerie L, Sokol H, Pariente B, Seksik P, Cosnes J. Changes in the Lémann Index Values During the First Years of Crohn's Disease. Clin Gastroenterol Hepatol 2015;13:1633-40.e3. [PMID: 25766650 DOI: 10.1016/j.cgh.2015.02.041] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
553 Verstockt B, Cleynen I. Genetic Influences on the Development of Fibrosis in Crohn's Disease. Front Med (Lausanne) 2016;3:24. [PMID: 27303667 DOI: 10.3389/fmed.2016.00024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
554 . UEG Week 2016 Poster Presentations. United European Gastroenterology Journal 2016;4:A157-720. [DOI: 10.1177/2050640616663689] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
555 Schmidt C, Bachmann O, Baumgart DC, Goetz M, Drvarov O, Kucharzik TF, Kühbacher T, Langhorst J, Maul J, Mohl W, Mudter J, Repp M, Sturm A, Witzemann D, Atreya R. [Position paper on endoscopic reporting in IBD]. Z Gastroenterol 2021. [PMID: 34284522 DOI: 10.1055/a-1504-9782] [Reference Citation Analysis]
556 Dubinsky MC, Lin YC, Dutridge D, Picornell Y, Landers CJ, Farrior S, Wrobel I, Quiros A, Vasiliauskas EA, Grill B. Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am J Gastroenterol. 2006;101:360-367. [PMID: 16454844 DOI: 10.1111/j.1572-0241.2006.00456.x] [Cited by in Crossref: 203] [Cited by in F6Publishing: 169] [Article Influence: 13.5] [Reference Citation Analysis]
557 van der Linde K, Boor PP, Houwing-Duistermaat JJ, Crusius BJ, Wilson PJ, Kuipers EJ, de Rooij FW. CARD15 mutations in Dutch familial and sporadic inflammatory bowel disease and an overview of European studies. Eur J Gastroenterol Hepatol. 2007;19:449-459. [PMID: 17489054 DOI: 10.1097/01.meg.0000236887.44214.6a] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
558 Viganò L, Mineccia M, Bertolino F, Giraldi F, Rigazio C, Rocca R, Ferrero A. Intraoperative ultrasonography in patients undergoing surgery for Crohn’s disease. Prospective evaluation of an innovative approach to optimize staging and treatment planning. Updates Surg 2019;71:305-12. [DOI: 10.1007/s13304-019-00668-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]